WO2017209136A1 - リン酸カルシウム成形体の製造方法、リン酸カルシウム成形体及び移植用材料 - Google Patents
リン酸カルシウム成形体の製造方法、リン酸カルシウム成形体及び移植用材料 Download PDFInfo
- Publication number
- WO2017209136A1 WO2017209136A1 PCT/JP2017/020130 JP2017020130W WO2017209136A1 WO 2017209136 A1 WO2017209136 A1 WO 2017209136A1 JP 2017020130 W JP2017020130 W JP 2017020130W WO 2017209136 A1 WO2017209136 A1 WO 2017209136A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium phosphate
- molded body
- calcium
- powder
- phosphate molded
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/222—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/427—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of other specific inorganic materials not covered by A61L27/422 or A61L27/425
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B28—WORKING CEMENT, CLAY, OR STONE
- B28B—SHAPING CLAY OR OTHER CERAMIC COMPOSITIONS; SHAPING SLAG; SHAPING MIXTURES CONTAINING CEMENTITIOUS MATERIAL, e.g. PLASTER
- B28B1/00—Producing shaped prefabricated articles from the material
- B28B1/001—Rapid manufacturing of 3D objects by additive depositing, agglomerating or laminating of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B28—WORKING CEMENT, CLAY, OR STONE
- B28B—SHAPING CLAY OR OTHER CERAMIC COMPOSITIONS; SHAPING SLAG; SHAPING MIXTURES CONTAINING CEMENTITIOUS MATERIAL, e.g. PLASTER
- B28B1/00—Producing shaped prefabricated articles from the material
- B28B1/30—Producing shaped prefabricated articles from the material by applying the material on to a core or other moulding surface to form a layer thereon
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C67/00—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/447—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on phosphates, e.g. hydroxyapatite
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/04—Materials or treatment for tissue regeneration for mammary reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
- C04B2111/00474—Uses not provided for elsewhere in C04B2111/00
- C04B2111/00836—Uses not provided for elsewhere in C04B2111/00 for medical or dental applications
Definitions
- the present invention relates to a method for producing a calcium phosphate molded article by discharging an organic acid solution in a droplet state from a nozzle portion and dropping it onto a layer containing calcium phosphate powder.
- the present invention further relates to a calcium phosphate molded body.
- the invention further relates to an implantable material.
- Regenerative medicine is a medical technology that regenerates the same form and function as the original tissue using one or more of cells, scaffolds, and growth factors in biological tissues that cannot be recovered only by the natural healing ability of the living body. is there.
- a calcium phosphate molded body may be used.
- Patent Document 1 describes a calcium phosphate cement and a calcium phosphate powder used for medical and dental purposes. Specifically, Patent Document 1 discloses a calcium phosphate cement obtained by kneading a calcium phosphate powder and a curing liquid agent, and the powder-liquid ratio of the powder and liquid agent is 1.5-3. A calcium phosphate cement having a consistency defined by JIS T6602 of 2 to 100 mm when it is changed in the range of 5 is described. In Patent Document 2, a) a powder layer forming step of forming a powder aggregate composed of an inorganic component such as calcium phosphate and other bone components into a flat powder layer; and b) biocompatible with a part of the powder layer.
- An artificial bone forming method by a powder lamination method having a forming step is described.
- Patent Document 3 a mixed solution containing a calcium solution and a phosphoric acid solution was prepared. At that time, a base material composed of calcium phosphate was present in the mixed solution, and thus calcium phosphate was precipitated on the base material, and thus obtained.
- a method for producing a calcium phosphate bone filling material in which the composite is heat treated is described.
- Patent Document 4 is a tissue regeneration member including a biodegradable resin film containing cytokine and calcium phosphate, and has a gradient structure in which the ratio of cytokine and calcium phosphate continuously increases or decreases in the thickness direction. It is described that the tissue regeneration member is formed by an inkjet method.
- Patent Document 5 discloses a layered modeling powder material containing calcium phosphate powder, wherein an organic compound having a phosphate group or a carboxyl group is applied to the surface of the calcium phosphate powder in a predetermined amount.
- a layered modeling powder material containing a predetermined amount of powder composed of an organic compound having a carboxyl group and having a hydroxyapatite (HAp) transition rate of 1% or less of a cured product obtained by curing the layered modeling powder material.
- HAp hydroxyapatite
- JP 2001-95913 A International Publication WO2005 / 011536 JP 2006-25915 A JP 2013-106721 A Japanese Patent Laying-Open No. 2015-187058
- This invention made it the subject which should be solved to provide the method of manufacturing the calcium-phosphate molded object which has high intensity
- the present inventors have found that a layer containing calcium phosphate powder having a Ca / P (calcium / phosphorus) atomic ratio of 1.4 to 1.8 is formed on the substrate.
- the organic acid solution having a solubility of calcium salt of organic acid in water of 1 g / 100 mL or less and pH of 3.5 or less is discharged in a droplet state from the nozzle portion, and contains the above-mentioned calcium phosphate powder. It has been found that a calcium phosphate molded body having high strength can be produced quickly and with high modeling accuracy by being dropped onto the layer.
- the present invention has been completed based on these findings.
- Step a of forming a layer containing calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8 on the substrate; and the solubility of the organic acid calcium salt in water is 1 g / 100 mL
- Step b for producing a calcium phosphate molded body; The manufacturing method of the calcium-phosphate molded object containing this.
- ⁇ 2> The production of a calcium phosphate molded article according to ⁇ 1>, wherein the organic acid used in the step b is at least one selected from the group consisting of citric acid, oxalic acid, tartaric acid, malonic acid, and malic acid.
- the organic acid used in the step b is at least one selected from the group consisting of citric acid, oxalic acid, tartaric acid, malonic acid, and malic acid.
- step b Forming a layer containing a calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8 on the layer containing the calcium phosphate powder formed in step a; and An organic acid solution having a calcium salt solubility in water of 1 g / 100 mL or less and a pH of 3.5 or less is ejected from the nozzle portion in a droplet state, and the calcium phosphate powder formed from the organic acid solution in step c is obtained.
- step d The calcium phosphate molded article according to ⁇ 3>, wherein the organic acid used in step d is at least one selected from the group consisting of citric acid, oxalic acid, tartaric acid, malonic acid, and malic acid.
- the calcium phosphate powder includes a first calcium phosphate powder and a second calcium phosphate powder, and the solubility of the first calcium phosphate powder in the organic acid is more than the solubility of the second calcium phosphate powder in the organic acid.
- the calcium phosphate powder including the first calcium phosphate powder and the second calcium phosphate powder includes at least particles having a particle diameter of 5 to 15 ⁇ m and particles having a particle diameter of 25 to 100 ⁇ m, and particles having a particle diameter of 25 ⁇ m or more on a volume basis.
- the flow function of the first calcium phosphate powder is less than 4.00
- fc and the maximum principal stress are ⁇ 1, it is expressed as ⁇ 1 / fc.
- ⁇ 7> The calcium phosphate molded body according to any one of ⁇ 1> to ⁇ 6>, wherein the concentration of the organic acid solution in step b and / or step d is 1.1 mol / L or more and 1.4 mol / L or less. Production method.
- ⁇ 8> The method for producing a calcium phosphate molded body according to ⁇ 7>, wherein the organic acid in step b and / or step d is citric acid.
- Production method. ⁇ 10> The method for producing a calcium phosphate molded body according to any one of ⁇ 1> to ⁇ 9>, wherein the pH of the organic acid solution in step b and / or step d is 2.5 or more and 3.5 or less.
- ⁇ 11> The method for producing a calcium phosphate molded body according to any one of ⁇ 1> to ⁇ 10>, further including a step e of removing the calcium phosphate powder that has not been used for forming the molded body.
- step e After the step e, including a step f for curing the molded body by immersing the molded body in an aqueous solution and / or a step g for curing the molded body by heating the molded body.
- the manufacturing method of the calcium-phosphate molded object of description ⁇ 13>
- ⁇ 14> The method for producing a calcium phosphate molded article according to ⁇ 13>, wherein the biocompatible polymer is recombinant gelatin.
- ⁇ 15> The method for producing a calcium phosphate molded article according to ⁇ 13> or ⁇ 14>, further comprising a step i of seeding the biocompatible polymer with cells after the step h.
- ⁇ 16> The method for producing a calcium phosphate molded body according to any one of ⁇ 1> to ⁇ 15>, wherein the calcium phosphate molded body is a scaffold for regenerative medicine or a tissue repair material.
- ⁇ 17> A calcium phosphate molded body manufactured by the method for manufacturing a calcium phosphate molded body according to any one of ⁇ 1> to ⁇ 16>.
- ⁇ 18> The calcium phosphate molded article according to ⁇ 17>, which is a scaffold for regenerative medicine or a tissue repair material.
- ⁇ 19> The calcium phosphate molded article according to ⁇ 17> or ⁇ 18>, which has a hole communicating with an external space.
- ⁇ 20> The calcium phosphate molded body according to ⁇ 19>, wherein the hole communicating with the external space passes through the inside of the molded body and communicates with the external space at both ends of the hole.
- ⁇ 21> The calcium phosphate molded body according to ⁇ 19> or ⁇ 20>, wherein the average diameter of the holes communicating with the external space is 200 ⁇ m to 2000 ⁇ m.
- ⁇ 22> A calcium phosphate molded body formed of calcium phosphate having a Ca / P atomic ratio of 1.4 to 1.8, the first hole communicating with the external space, and the first hole The calcium-phosphate molded object which has a 2nd hole whose average diameter is larger than this.
- ⁇ 23> The calcium phosphate molded body according to ⁇ 22>, wherein the average diameter of the first holes communicating with the external space is 200 ⁇ m to 2000 ⁇ m.
- ⁇ 24> The calcium phosphate molding according to ⁇ 22> or ⁇ 23>, wherein the number of first holes communicating with the external space is larger than the number of second holes having an average diameter larger than that of the first holes. body.
- a transplantable material comprising a calcium phosphate molded body in which a part or all of the surface is coated with recombinant gelatin.
- ⁇ 29> The transplant material according to any one of ⁇ 25> to ⁇ 28>, wherein the calcium phosphate molded body is in a block shape.
- ⁇ 30> The transplant material according to any one of ⁇ 25> to ⁇ 28>, wherein the calcium phosphate molded body is granular.
- the specific gravity is 0.7 g / mL or more and / or the porosity by mercury injection method is 75% or less,
- the water absorption permeation rate is 0.05 mm / second or more.
- One end of a plastic cylinder having an inner diameter of 2 mm is connected to a calcium phosphate molded body having a diameter of 8 mm and a height of 20 mm, the other end of the plastic cylinder is connected to one end of a tube having a length of 100 mm, and the other end of the tube is connected to a 10 mL syringe.
- ⁇ 33> It has a structure in which relatively dense layers and relatively sparse layers discriminated by measurement by nanofocus X-ray CT or microfocus X-ray CT are alternately stacked, ⁇ 31> Or the calcium-phosphate molded object as described in ⁇ 32>.
- ⁇ 34> The calcium phosphate molded article according to ⁇ 33>, wherein at least 5 or more relatively dense layers and at least 5 or more relatively sparse layers are alternately laminated.
- the pitch between the first relatively dense layer and the second relatively dense layer adjacent to the first relatively dense layer is 50 to 300 ⁇ m, ⁇ 33> or ⁇ 34>
- ⁇ 36> Based on a nanofocus X-ray CT image of a calcium phosphate molded body, in a waveform diagram in which the distance in one direction of the molded body is displayed on the horizontal axis and the relative CT intensity is displayed on the vertical axis, the peak of the peak and the peak of the valley ⁇ 31> or ⁇ 32> The calcium phosphate molded product according to ⁇ 32>.
- ⁇ 37> The calcium phosphate molded article according to ⁇ 36>, which has at least five peak peaks.
- ⁇ 38> The calcium phosphate molded body according to ⁇ 36> or ⁇ 37>, wherein the pitch between the first peak and the second peak adjacent to the first peak is 50 to 300 ⁇ m. .
- a calcium phosphate molded body having high strength can be manufactured quickly and with high modeling accuracy.
- the calcium phosphate molded body of the present invention has high strength.
- the transplant material of the present invention is excellent in cell adhesion and has high bone forming ability.
- FIG. 1 shows a molded body having an X communication hole, a Y communication hole, and a Z communication hole of the first hole.
- FIG. 2 shows a shaped body having a structural reinforcement region.
- FIG. 3 is a design diagram for producing a molded body by a 3D printer.
- FIG. 4 shows the produced compact.
- FIG. 5 shows the results of confirming the recombinant gelatin modification effect (cell adhesion) on ⁇ -TCP particles.
- FIG. 6 shows the results of confirming the recombinant gelatin modification effect (bone formation) on ⁇ -TCP particles.
- FIG. 7 shows an experimental system used for measuring the water absorption rate.
- FIG. 8 shows the structure of the object used for the analysis of the sparsely laminated structure.
- FIG. 10 shows a state in which a region of 3.14 mm in the Z-axis direction and 3.14 mm in the X-axis direction is selected in the nanofocus X-ray CT analysis.
- FIG. 11 shows a waveform of the area selected in FIG. 10 in accordance with the degree of black and white.
- FIG. 12 shows a state where an area of 3.12 mm in the Z-axis direction and 3.12 mm in the Y-axis direction is selected in the nanofocus X-ray CT analysis.
- FIG. 13 shows a waveform of the region selected in FIG. 12 according to the degree of black and white.
- FIG. 14 shows the measurement results of the particle size distribution of the mixed powder.
- FIG. 15 shows the measurement result of the particle size distribution of the TTCP powder.
- FIG. 16 shows the measurement results of the particle size distribution of DCPD powder.
- FIG. 17 shows a schematic view of a calcium phosphate molded article used in the rat test.
- FIG. 18 shows the results of microfocus CT analysis for test A (control: defect only).
- FIG. 19 shows the results of micro-CT analysis for 8 weeks after transplantation of molded product B into rats.
- FIG. 20 shows the results of micro CT analysis of the transplanted molded product B every 0 to 2 weeks.
- FIG. 21 shows the results of micro CT analysis of the transplanted molded product B after 8 weeks.
- FIG. 22 shows the results of pathological specimen and H & E staining after 8 weeks of the transplanted molded product B.
- FIG. 23 shows the results of the pathological specimen and H & E staining of the transplanted molded body B after 8 weeks of the rat (second animal).
- FIG. 24 shows the results of pathological specimens and rat H & E staining after 8 weeks for the transplanted molded body B in rats (second animal).
- FIG. 25 shows the result of von ⁇ Kossa staining of a pathological specimen 8 weeks after the rat (third) of the transplanted molded body B.
- FIG. 26 shows a sample of classes 1 to 5 in the evaluation of the warpage of the bottom surface.
- FIG. 27 shows the relationship between the coating amount and the compressive strength of the calcium phosphate molded body.
- FIG. 28 shows the relationship between the coating amount and the warpage of the bottom surface of the calcium phosphate molded body.
- FIG. 29 shows the relationship between the compressive strength and the warp of the bottom surface of the calcium phosphate molded body.
- FIG. 30 is a schematic view of a calcium phosphate molded body having three-stage communication holes.
- FIG. 31 shows a Scanning Electron Microscope (SEM) image of a calcium phosphate molded body having three stages of communication holes.
- SEM Scanning Electron Microscope
- a numerical range expressed using “to” means a range including numerical values described before and after “to” as a lower limit value and an upper limit value.
- Method for producing calcium phosphate molded body comprises: Forming a layer containing a calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8 on the substrate; and the solubility of the calcium salt of the organic acid in water is 1 g / 100 mL or less. And discharging an organic acid solution having a pH of 3.5 or less from the nozzle portion in the form of droplets, and dropping the organic acid solution onto the layer containing the calcium phosphate powder formed in the step a, thereby forming a calcium phosphate molded body.
- Manufacturing step b including.
- a calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8 is used, the solubility of the organic acid calcium salt in water is 1 g / 100 mL or less, and the pH is 3
- an organic acid solution that is less than or equal to .5 a calcium phosphate molded body having high strength can be produced quickly and with high modeling accuracy (high droplet bleeding prevention property).
- Calcium phosphate is precipitated as calcium hydrogen phosphate (also referred to as CaHPO 4 : DCPA) having a Ca / P atomic ratio of 1 at pH 4 or lower.
- DCPA calcium hydrogen phosphate
- an organic acid solution having a pH of 3.5 or less is used. This is because the pH changes after ejection, specifically, as DCPA having a Ca / P atomic ratio of 1 is precipitated. This is because the pH is shifted to the alkali side.
- excess Ca is solidified as a low-solubility salt, and the effects of “high curing rate”, “high strength of the molded product”, and “improved accuracy of the molded product by preventing bleeding of droplets” are achieved.
- the “calcium phosphate molded body having high strength” as used in the present specification has such a strength that the calcium phosphate molded body can withstand handling after molding (for example, an operation of taking out the molded body from the apparatus). Means that.
- the ratio of the number of Ca / P atoms is 1.4 to 1.8.
- the ratio of the number of Ca / P atoms is preferably 1.45 to 1.79, more preferably 1.50 to 1.70.
- the method for producing the calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8 is not particularly limited.
- two or more types of calcium phosphate powders having a known Ca / P atomic ratio are used. When used as a raw material, the two or more types of calcium phosphate powders are mixed at a predetermined ratio so that the ratio of the number of Ca / P atoms is 1.4 to 1.8.
- a calcium phosphate powder having a ratio of 1.4 to 1.8 can be produced.
- Ca 4 (PO 4 ) 2 O tetracalcium phosphate: also referred to as TTCP: Ca / P atomic ratio is 2.0
- CaHPO 4 .2H 2 O Calcium hydrogen phosphate dihydrate: also referred to as DCPD: The ratio of the number of Ca / P atoms is 1.0), and the mixing ratio of TTCP and DCPD is changed to obtain the number of Ca / P atoms.
- a calcium phosphate powder having a ratio of 1.4 to 1.8 can be produced.
- the particle size of the powder is preferably 1 ⁇ m to 100 ⁇ m, more preferably 5 ⁇ m to 50 ⁇ m, and even more preferably. Is from 10 ⁇ m to 30 ⁇ m.
- the particle size can be measured by a laser diffraction / scattering particle size distribution measuring method, and specifically, a laser diffraction / scattering particle size distribution measuring device / manufactured by HORIBA, Ltd./LA-920, or LMS manufactured by Seishin Corporation. It can be measured by -2000e.
- the calcium phosphate powder includes a first calcium phosphate powder and a second calcium phosphate powder, and the solubility of the first calcium phosphate powder in an organic acid (described later) is higher than that of the second calcium phosphate powder (described later). ).
- the calcium phosphate powder including the first calcium phosphate powder and the second calcium phosphate powder includes at least particles having a particle size of 5 to 15 ⁇ m and particles having a particle size of 25 to 100 ⁇ m, and having a particle size of 5 to 15 ⁇ m.
- Particles on a volume basis are 5.0% or more (more preferably 10% or more, more preferably 15% or more included), and particles having a particle diameter of 25 ⁇ m or more are 20% or more (more preferably 25% or more, more preferably 30%) on a volume basis. %) Included.
- the flow function of the first calcium phosphate powder is less than 4.00, and the flow function of the calcium phosphate powder including the first calcium phosphate powder and the second calcium phosphate powder is 4.00 or more.
- the flow function is expressed by ⁇ 1 / fc when the fracture strength is fc and the maximum principal stress is ⁇ 1.
- the flow function can be measured according to the description of the examples described later using a measuring device such as “Powder Flow Tester, PFT” manufactured by Brookfield.
- Step a in the present invention is a step of forming a layer containing calcium phosphate powder on the substrate.
- the material, shape, and size of the substrate are not particularly limited, and an appropriate substrate can be used according to the purpose.
- As the substrate a substrate having a plane with a predetermined area is preferable.
- the surface area of the substrate is not particularly limited, but is preferably 5 to 200 cm 2 , more preferably 20 to 100 cm 2 .
- Examples of the material of the substrate include plastic materials such as acrylic, methacryl (polymethyl methacrylate resin, etc.), polystyrene, and polypropylene, inorganic materials such as glass, and metal materials such as copper, aluminum, and stainless steel.
- the step of forming the layer containing the calcium phosphate powder on the substrate can be performed by any method, and the method is not particularly limited, but can be performed using, for example, a 3D printer (three-dimensional printer).
- a 3D printer three-dimensional printer
- Z-Printer310 Plus (3D Systems Corporation (former Z Corporation)
- the like can be used, but is not particularly limited.
- the solubility with respect to the water of the calcium salt of organic acid is 1 g / 100 mL or less, and the organic acid solution whose pH is 3.5 or less is used.
- the solubility of the calcium salt of an organic acid means the solubility at a temperature of 25 ° C.
- the solubility of the calcium salt of the organic acid in water may be 1 g / 100 mL or less, preferably 0.5 g / 100 mL or less, more preferably 0.1 g / 100 mL or less.
- the organic acid satisfying the above solubility is preferably at least one selected from the group consisting of citric acid, oxalic acid, tartaric acid, malonic acid and malic acid, more preferably citric acid, oxalic acid or tartaric acid, Citric acid is more preferred.
- the pH of the organic acid solution is 5 or less, preferably 1.0 to 3.5, more preferably 2.5 or more and 3.5 or less, and further preferably 3.0 or more and 3.5 or less.
- An organic acid solution having a pH of 3.5 or less can be produced by adjusting the mixing ratio of an organic acid and a salt of an organic acid (such as a sodium salt of an organic acid).
- the concentration of the organic acid in the organic acid solution is not particularly limited, but is generally from 0.1 mol / L to 5.0 mol / L, preferably from 0.5 mol / L to 3.0 mol / L. More preferably, they are 1.0 mol / L or more and 2.0 mol / L or less, More preferably, they are 1.1 mol / L or more and 1.4 mol / L or less.
- Step b for producing a calcium phosphate molded body including discharge of an organic acid solution an organic acid solution is ejected from the nozzle portion in a droplet state, and the organic acid solution is dropped onto the layer containing the calcium phosphate powder formed in step a, thereby producing a calcium phosphate molded body.
- the organic acid solution is ejected in the form of droplets.
- the liquid droplet state is a state in which the organic acid solution discharged from the nozzle portion moves in the space without contacting either the nozzle portion or the layer containing calcium phosphate powder on the substrate.
- the temperature at which the organic acid solution is discharged in a droplet state is not particularly limited, but is generally 15 ° C. or higher and 50 ° C. or lower, preferably 20 ° C. or higher and 40 ° C. or lower. Room temperature.
- the discharge of the organic acid solution can be performed using an inkjet head having a nozzle portion.
- Inkjet recording apparatuses are known in which ink droplets are ejected from a nozzle portion by an actuator of a piezo element and landed on a medium to form an image on the medium. In the ink jet recording apparatus, the arrangement pitch of the nozzle portions is increased, and minute ink droplets of several picoliters to 100 picoliters can be ejected.
- Japanese Patent Application Laid-Open No. 2012-4555 describes a method and an apparatus for producing a functional material by an ink jet method, and the discharge of an organic acid solution is an ink jet head as described in Japanese Patent Application Laid-Open No. 2012-4555. Can be used. The contents described in JP 2012-4555 A are all cited in this specification.
- the inkjet head is preferably configured to be freely movable in the horizontal direction.
- the inkjet head may be moved with respect to the fixed substrate, or both the inkjet head and the substrate may be moved.
- the ink jet head ejects ink (that is, an organic acid solution) supplied from an ink tank to a desired position of a layer containing powder on a substrate.
- the ink jet system either a continuous type or an on-demand type may be used, but when discharging to a large area of several tens of centimeters or more, an on-demand type having a plurality of nozzles is preferable.
- Various methods such as a piezo method, a thermal method, a solid method, and an electrostatic suction method can be used as an actuator that characterizes an on-demand type discharge method.
- the piezo method can discharge an organic solvent system in addition to an aqueous system.
- the nozzles may be arranged in a single row, in a plurality of rows, or in a staggered pattern.
- the step b of producing the calcium phosphate molded body including the discharge of the organic acid solution can be performed using, for example, a 3D printer (three-dimensional printer) equipped with an inkjet head.
- a 3D printer three-dimensional printer equipped with an inkjet head.
- Z-Printer310 Plus (3D Systems Corporation (former Z Corporation)
- the like can be used, but is not particularly limited.
- the size of the calcium phosphate molded body produced by the method of the present invention is not particularly limited, but when the calcium phosphate molded body is approximated to a rectangular parallelepiped, the vertical, horizontal, and height of the rectangular parallelepiped are each preferably 0.1 mm to 200 mm. More preferably, it is 1 mm to 100 mm.
- the method for producing a calcium phosphate molded body according to the present invention comprises the above step b, Forming a layer containing a calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8 on the layer containing the calcium phosphate powder formed in step a; and calcium organic acid Contains calcium phosphate powder in which the organic acid solution having a solubility in water of salt of 1 g / 100 mL or less and having a pH of 3.5 or less is discharged in a droplet state from the nozzle portion, and the organic acid solution is formed in step c.
- Said process c can be performed similarly to the process a.
- the type of material used in step c may be the same as or different from step a, but is preferably the same.
- Said process d can be performed like the process b.
- the type of material used in step d may be the same as or different from step b, but is preferably the same.
- the organic acid used in step d is preferably at least one selected from the group consisting of citric acid, oxalic acid, tartaric acid, malonic acid and malic acid, as in step b. Acid or tartaric acid is more preferable, and citric acid is more preferable.
- the number of times is not particularly limited, and the number of times can be any number of one or more, for example, 1 to 1000 times.
- the coating amount of the organic acid solution in step b and / or step d is generally 0.10 g / cm 3 or more and 0.40 g / cm 3 or less, preferably 0.20 g / cm 3 or more and 0.30 g. / Cm 3 or less.
- a step e of removing calcium phosphate powder that has not been used for forming a molded body can be further provided.
- To remove the calcium phosphate powder is to remove the calcium phosphate powder from the surface of the molded body.
- the formed body formed into a desired shape can be recovered.
- the calcium phosphate powder that has not been used for forming the molded body can be removed without damaging the molded body.
- the method for removing the calcium phosphate powder that has not been used for forming the molded body is not particularly limited, and for example, compressed air may be used.
- Step of curing the molded body after the step e of removing the calcium phosphate powder that has not been used for forming the molded body, the step of curing the molded body by immersing the molded body in an aqueous solution, And / or the process g which hardens a molded object by heating a molded object can be further provided.
- the process f and the process g may be provided or may not be provided.
- strength of a molded object can be raised more by hardening a molded object by the process f. . It is presumed that the strength of the molded body is further increased due to the improvement in strength between the layers containing calcium phosphate powder. That is, in a preferred embodiment of the present invention, after performing step a and step b, step c and step d are performed, and then step e of removing calcium phosphate powder that has not been used to form a molded body is performed. After the step e, the step f of curing the molded body can be performed by immersing the molded body in an aqueous solution.
- the type of the aqueous solution used in the step f of curing the molded body by immersing the molded body in an aqueous solution is not particularly limited as long as the molded body can be cured, and examples thereof include a phosphoric acid aqueous solution.
- a 0.1 mol / L to 1.0 mol / L sodium dihydrogen phosphate solution can be used.
- the pH of the aqueous solution is not particularly limited, but is generally pH 3 to 11, preferably pH 3 to 10, and more preferably pH 4 to 9.
- the time for immersing the molded body in the aqueous solution is not particularly limited, but is generally 1 hour to 48 hours, preferably 2 hours to 24 hours, more preferably 4 hours to 24 hours.
- the molded body is generally 100 ° C. to 2000 ° C., preferably 200 ° C. to 1500 ° C., more preferably 500 ° C. to 1500 ° C. It can be carried out by heating at a temperature of preferably 1000 ° C. to 1300 ° C., particularly preferably 1100 ° C. to 1200 ° C.
- T [Kelvin: K] t [degree of Celsius: ° C.] + 273.15.
- the heating time is not particularly limited, but is generally 1 hour to 48 hours, preferably 1 hour to 24 hours, more preferably 2 hours to 12 hours, and further preferably 2 hours to 6 hours. It is. Heating can be performed by a conventional method using a muffle furnace or the like.
- Compressive strength of the molded body can be increased by performing the process f and / or the process g for curing the molded body.
- the compressive strength of the molded article subjected to step f and / or step g is not particularly limited, but is preferably 2.5 MPa or more, more preferably 3.0 MPa or more, and further preferably 3.5 MPa or more,
- the upper limit of the compressive strength is not particularly limited, but is generally 10 MPa or less.
- a step h of coating the molded body with the biocompatible polymer can be further provided.
- the step h may be provided or may not be provided.
- the biocompatible polymer preferably described later
- the reaction between the biocompatible polymer and the acid can be prevented. That is, in a preferred embodiment of the present invention, after performing the step f and / or the step g for curing the molded body, the step h for coating the molded body with the biocompatible polymer can be performed.
- Bioaffinity polymer means that a significant adverse reaction such as a long-term and chronic inflammatory reaction is not caused upon contact with a living body.
- the biocompatible polymer is not particularly limited as to whether or not it is degraded in vivo as long as it has affinity for the living body, but is preferably a biodegradable polymer.
- Specific examples of non-biodegradable materials include polytetrafluoroethylene (PTFE), polyurethane, polypropylene, polyester, vinyl chloride, polycarbonate, acrylic, stainless steel, titanium, silicone, and MPC (2-methacryloyloxyethyl phosphorylcholine). Can be mentioned.
- biodegradable material examples include naturally occurring peptides, recombinant peptides (RCP) or polypeptides such as chemically synthesized peptides (for example, gelatin described below), polylactic acid, polyglycolic acid, lactic acid, Examples include glycolic acid copolymer (PLGA), hyaluronic acid, glycosaminoglycan, proteoglycan, chondroitin, cellulose, agarose, carboxymethylcellulose, chitin, and chitosan. Among the above, a recombinant peptide is particularly preferable. These biocompatible polymers may be devised to enhance cell adhesion.
- cell adhesion substrate fibronectin, vitronectin, laminin
- cell adhesion sequence expressed by amino acid single letter notation, RGD sequence, LDV sequence, REDV sequence, YIGSR sequence, PDSGR sequence, RYVVLPR, Sequence, LGTIPG sequence, RNIAEIIKDI sequence, IKVAV sequence, LRE sequence, DGEA sequence, and HAV sequence
- a method such as “hydrophilic treatment” can be used.
- polypeptide containing recombinant peptide or chemically synthesized peptide is not particularly limited as long as it has biocompatibility, for example, gelatin, collagen, elastin, fibronectin, pronectin, laminin, tenascin, fibrin, fibroin, enteractin, Thrombospondin and retronectin are preferable, and gelatin, collagen and atelocollagen are most preferable.
- the gelatin used in the present invention is preferably natural gelatin, recombinant gelatin or chemically synthesized seratin, and more preferably recombinant gelatin.
- Natural gelatin means gelatin made from naturally derived collagen.
- the organism from which gelatin is derived is not particularly limited, and for example, gelatin derived from animals (mammals, fish, etc.) can be used.
- a chemically synthesized peptide or chemically synthesized gelatin means an artificially synthesized peptide or gelatin.
- the peptide such as gelatin may be synthesized by solid phase synthesis or liquid phase synthesis, but is preferably solid phase synthesis.
- Solid-phase synthesis of peptides is known to those skilled in the art. For example, Fmoc group synthesis method using Fmoc group (Fluorenyl-Methoxy-Carbonyl group) as amino group protection, and Boc group (tert-Butyl group) as amino group protection Boc group synthesis method using Oxy Carbonyl group).
- the preferred embodiment of the chemically synthesized gelatin can be applied to the contents described in the recombinant gelatin described later in this specification. Recombinant gelatin will be described later in this specification.
- the hydrophilic value “1 / IOB” value of the biocompatible polymer is preferably 0 to 1.0. More preferably, it is 0 to 0.6, and still more preferably 0 to 0.4.
- IOB is an index of hydrophilicity / hydrophobicity based on an organic conceptual diagram representing the polarity / nonpolarity of an organic compound proposed by Satoshi Fujita, and details thereof are described in, for example, “Pharmaceutical Bulletin”, vol. 2, 2, pp. .163-173 (1954), “Chemical Field” vol.11, 10, pp.719-725 (1957), “Fragrance Journal”, vol.50, pp.79-82 (1981), etc. Yes.
- methane (CH 4 ) is the source of all organic compounds, and all the other compounds are all methane derivatives, with certain numbers set for their carbon number, substituents, transformations, rings, etc. Then, the score is added to obtain an organic value (OV) and an inorganic value (IV), and these values are plotted on a diagram with the organic value on the X axis and the inorganic value on the Y axis. It is going.
- the IOB in the organic conceptual diagram refers to the ratio of the inorganic value (IV) to the organic value (OV) in the organic conceptual diagram, that is, “inorganic value (IV) / organic value (OV)”.
- hydrophilicity / hydrophobicity is represented by a “1 / IOB” value obtained by taking the reciprocal of IOB. The smaller the “1 / IOB” value (closer to 0), the more hydrophilic it is.
- the biocompatible polymer used in the present invention is a polypeptide
- the hydrophilicity / hydrophobicity index represented by Grand ⁇ average of hydropathicity (GRAVY) value 0.3 or less, preferably minus 9.0 or more, More preferably, it is 0.0 or less and minus 7.0 or more.
- Grand average of hydropathicity (GRAVY) values are: Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins MR, Appel RD, Bairoch A.; Protein Identification and Analysis Tools on the ExPASy Server John M. Walker (ed): The Proteomics Protocols Handbook, Humana Press (2005). Pp.
- the biocompatible polymer may be cross-linked or non-cross-linked.
- Common crosslinking methods include thermal crosslinking, crosslinking with aldehydes (eg, formaldehyde, glutaraldehyde, etc.), crosslinking with condensing agents (carbodiimide, cyanamide, etc.), enzyme crosslinking, photocrosslinking, UV crosslinking, hydrophobic interaction, Hydrogen bonding, ionic interaction, and the like are known, and the above-described crosslinking method can also be used in the present invention.
- the crosslinking method used in the present invention is more preferably thermal crosslinking, ultraviolet crosslinking, or enzyme crosslinking, and particularly preferably thermal crosslinking.
- the enzyme When performing cross-linking with an enzyme, the enzyme is not particularly limited as long as it has a cross-linking action between polymer materials, but preferably trans-glutaminase and laccase, most preferably trans-glutaminase can be used for cross-linking.
- a specific example of the protein that is enzymatically cross-linked with transglutaminase is not particularly limited as long as it is a protein having a lysine residue and a glutamine residue.
- the transglutaminase may be derived from a mammal or a microorganism. Specifically, transglutaminase derived from a mammal sold as an Ajinomoto Co., Ltd.
- Human-derived blood coagulation factors Factor XIIIa, Haematologic Technologies, Inc.
- Factor XIIIa Haematologic Technologies, Inc.
- guinea pig liver-derived transglutaminase goat-derived transglutaminase
- rabbit-derived transglutaminase from Oriental Yeast Kogyo Co., Ltd., Upstate USA Inc., Biodesign International, etc. Etc.
- the reaction temperature at the time of performing crosslinking is not particularly limited as long as crosslinking is possible, but is preferably ⁇ 100 ° C. to 500 ° C., more preferably 0 ° C. to 300 ° C., and still more preferably. It is 50 ° C to 300 ° C, more preferably 100 ° C to 250 ° C, and further preferably 120 ° C to 200 ° C.
- the gelatin used in the present invention is preferably recombinant gelatin.
- Recombinant gelatin means a polypeptide or protein-like substance having an amino acid sequence similar to gelatin produced by a genetic recombination technique.
- the recombinant gelatin that can be used in the present invention preferably has a repeating sequence represented by Gly-XY, which is characteristic of collagen (X and Y each independently represents an amino acid).
- Gly-XY which is characteristic of collagen (X and Y each independently represents an amino acid).
- the plurality of Gly-XY may be the same or different.
- two or more cell adhesion signals are contained in one molecule.
- recombinant gelatin used in the present invention recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen can be used.
- EP1014176, US Pat. No. 6,992,172, International Publication WO2004 / 85473, International Publication WO2008 / 103041, and the like can be used, but are not limited thereto.
- a preferable example of the recombinant gelatin used in the present invention is the recombinant gelatin of the following embodiment.
- Recombinant gelatin has excellent biocompatibility due to the inherent performance of natural gelatin, and is not naturally derived, so there is no concern about bovine spongiform encephalopathy (BSE) and excellent non-infectivity. Recombinant gelatin is more uniform than natural gelatin and its sequence is determined, so that strength and degradability can be precisely designed with less blur due to crosslinking or the like.
- BSE bovine spongiform encephalopathy
- the molecular weight of the recombinant gelatin is not particularly limited, but is preferably 2000 or more and 100000 or less (2 kDa (kilo dalton) or more and 100 kDa or less), more preferably 2500 or more and 95000 or less (2.5 kDa or more and 95 kDa or less), and further preferably. Is from 5,000 to 90,000 (5 kDa to 90 kDa), and most preferably from 10,000 to 90,000 (10 kDa to 90 kDa).
- the recombinant gelatin preferably has a repeating sequence represented by Gly-XY characteristic of collagen.
- the plurality of Gly-XY may be the same or different.
- Gly-XY Gly represents glycine
- X and Y are Represents any amino acid (preferably any amino acid other than glycine).
- the sequence represented by Gly-XY, which is characteristic of collagen, is a very specific partial structure in the amino acid composition and sequence of gelatin and collagen compared to other proteins. In this part, glycine accounts for about one third of the whole, and in the amino acid sequence, it is one in three repeats.
- Glycine is the simplest amino acid, has few constraints on the arrangement of molecular chains, and greatly contributes to the regeneration of the helix structure upon gelation.
- the amino acids represented by X and Y are rich in imino acids (proline, oxyproline), and preferably account for 10% to 45% of the total.
- 80% or more, more preferably 95% or more, and most preferably 99% or more of the amino acid sequence of the recombinant gelatin is a Gly-XY repeating structure.
- polar amino acids are charged and uncharged at 1: 1.
- the polar amino acid specifically refers to cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine, serine, threonine, tyrosine and arginine, and among these polar uncharged amino acids are cysteine, asparagine, glutamine, serine. Refers to threonine and tyrosine.
- the proportion of polar amino acids is 10 to 40%, preferably 20 to 30%, of all the constituent amino acids.
- the proportion of uncharged amino acids in the polar amino acid is preferably 5% or more and less than 20%, more preferably 5% or more and less than 10%. Furthermore, it is preferable that any one amino acid of serine, threonine, asparagine, tyrosine and cysteine is not included in the sequence, and that two or more amino acids of serine, threonine, asparagine, tyrosine and cysteine are not included in the sequence. More preferred.
- the minimum amino acid sequence that acts as a cell adhesion signal in a polypeptide is known (for example, “Pathophysiology”, Vol. 9, No. 7 (1990), page 527, published by Nagai Publishing Co., Ltd.).
- the recombinant gelatin used in the present invention preferably has two or more of these cell adhesion signals in one molecule.
- Specific sequences include RGD sequences, LDV sequences, REDV sequences, YIGSR sequences, PDSGR sequences, RYVVLPR sequences, LGITIPG sequences, RNIAEIIKDI sequences, which are expressed in one-letter amino acid notation in that many types of cells adhere.
- IKVAV sequences IKVAV sequences, LRE sequences, DGEA sequences, and HAV sequences are preferred. More preferred are RGD sequence, YIGSR sequence, PDSGR sequence, LGTIPG sequence, IKVAV sequence and HAV sequence, and particularly preferred is RGD sequence. Of the RGD sequences, an ERGD sequence is preferred. By using recombinant gelatin having a cell adhesion signal, the amount of cell substrate produced can be improved.
- the arrangement of RGD sequences in the recombinant gelatin used in the present invention is preferably such that the number of amino acids between RGDs is not uniform between 0 and 100, and more preferably the number of amino acids between RGDs is not uniform between 25 and 60. .
- the content of the minimum amino acid sequence is preferably 3 to 50, more preferably 4 to 30, and particularly preferably 5 to 20 per protein molecule from the viewpoint of cell adhesion and proliferation. Most preferably, it is 12.
- the ratio of the RGD motif to the total number of amino acids is preferably at least 0.4%.
- each stretch of 350 amino acids contains at least one RGD motif.
- the ratio of the RGD motif to the total number of amino acids is more preferably at least 0.6%, even more preferably at least 0.8%, even more preferably at least 1.0%, particularly preferably at least 1.2%. %, Most preferably at least 1.5%.
- the number of RGD motifs in the recombinant peptide is preferably at least 4, more preferably 6, more preferably 8, even more preferably 12 or more and 16 or less per 250 amino acids.
- a ratio of 0.4% of the RGD motif corresponds to at least one RGD sequence per 250 amino acids. Since the number of RGD motifs is an integer, a gelatin of 251 amino acids must contain at least two RGD sequences to meet the 0.4% feature.
- the recombinant gelatin of the present invention comprises at least 2 RGD sequences per 250 amino acids, more preferably comprises at least 3 RGD sequences per 250 amino acids, more preferably at least 4 per 250 amino acids. Contains the RGD sequence. As a further aspect of the recombinant gelatin of the present invention, it contains at least 4 RGD motifs, preferably 6, more preferably 8, more preferably 12 or more and 16 or less.
- Recombinant gelatin may be partially hydrolyzed.
- the recombinant gelatin used in the present invention is represented by A-[(Gly-XY) n ] m -B.
- n Xs independently represents any of amino acids
- n Ys independently represents any of amino acids.
- m is preferably an integer of 2 to 10, more preferably an integer of 3 to 5.
- n is preferably an integer of 3 to 100, more preferably an integer of 15 to 70, and most preferably an integer of 50 to 65.
- A represents any amino acid or amino acid sequence
- B represents any amino acid or amino acid sequence.
- the n Gly-XY may be the same or different.
- the recombinant gelatin used in the present invention is Gly-Ala-Pro-[(Gly-XY) 63 ] 3 -Gly (wherein 63 X independently represent any of amino acids, 63 Y's each independently represent any of the amino acids, wherein 63 Gly-XY may be the same or different.
- the naturally occurring collagen referred to here may be any naturally occurring collagen, but is preferably type I, type II, type III, type IV, or type V collagen. More preferred is type I, type II, or type III collagen.
- the collagen origin is preferably human, bovine, porcine, mouse or rat, more preferably human.
- the isoelectric point of the recombinant gelatin used in the present invention is preferably 5 to 10, more preferably 6 to 10, and further preferably 7 to 9.5.
- the measurement of the isoelectric point of recombinant gelatin was described in the isoelectric focusing method (see Maxey, CR (1976; Phitogr. Gelatin 2, Editor Cox, PJ Academic, London, Engl.). As described above, it can be carried out by measuring the pH after passing a 1% by weight gelatin solution through a mixed crystal column of cation and anion exchange resin.
- the recombinant gelatin is not deaminated.
- the recombinant gelatin has no telopeptide.
- the recombinant gelatin is a substantially pure polypeptide prepared with a nucleic acid encoding an amino acid sequence.
- a peptide comprising the amino acid sequence set forth in SEQ ID NO: 1; (2) A peptide having an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence described in SEQ ID NO: 1 and having biocompatibility; or (3) described in SEQ ID NO: 1 Any of peptides having an amino acid sequence having 80% or more (more preferably 90% or more, particularly preferably 95% or more, most preferably 98% or more) of amino acid sequence and biocompatibility. It is.
- sequence identity between two amino acid sequences can be determined by any method known to those skilled in the art, and the BLAST ((Basic Local Alignment Search Tool)) program (J. Mol. Biol. 215: 403-410, 1990) Etc. can be used to determine.
- amino acid sequence in which one or several amino acids are deleted, substituted or added is preferably 1 to 20, more preferably 1 to 10, and further preferably 1 to 5. Means, particularly preferably 1 to 3.
- the recombinant gelatin used in the present invention can be produced by a genetic recombination technique known to those skilled in the art. For example, in EP1014176A2, US Pat. No. 6,992,172, International Publication WO2004 / 85473, International Publication WO2008 / 103041, etc. It can be produced according to the method described. Specifically, a gene encoding the amino acid sequence of a predetermined recombinant gelatin is obtained, and this is incorporated into an expression vector to produce a recombinant expression vector, which is introduced into an appropriate host to produce a transformant. . Recombinant gelatin is produced by culturing the obtained transformant in an appropriate medium. Therefore, the recombinant gelatin used in the present invention can be prepared by recovering the recombinant gelatin produced from the culture. .
- the method of coating the molded body with the biocompatible polymer is not particularly limited, and a biocompatible polymer solution can be used.
- the solvent used in the biocompatible polymer solution is not particularly limited as long as it is a solvent that can dissolve the biocompatible polymer, but is generally water, an organic solvent, or a mixture of water and an organic solvent, Preferably, it is an aqueous medium such as water or a mixture of water and an organic solvent. Examples of the organic solvent include acetone and ethanol. In the case of a gelatin solution, an aqueous gelatin solution can be preferably used.
- the concentration of the biocompatible polymer in the biocompatible polymer solution is not particularly limited, but is generally 1 to 50% by mass, preferably 2 to 40% by mass, more preferably 3 to 30%. % By mass.
- the molded body can be coated with the biocompatible polymer.
- the molded body can be coated with the biocompatible polymer by immersing the molded body in a biocompatible polymer solution and drying it.
- step i of seeding cells on the biocompatible polymer after step h of coating the molded body with the biocompatible polymer is performed. Further, it can be provided.
- the use of the molded body in the present invention is intended to be a scaffold for regenerative medicine or a tissue repair material. However, when the cells are seeded and used in the molded body, the cells are not seeded in the molded body. It is assumed that it is used for
- the type of cells to be seeded is not particularly limited and can be appropriately selected depending on the purpose of use.
- the cell to be used is preferably an animal cell, more preferably a vertebrate cell, particularly preferably a human cell.
- Vertebrate-derived cells may be any of universal cells, somatic stem cells, progenitor cells, or mature cells.
- ES embryonic stem
- GS reproductive stem
- iPS induced pluripotent stem
- somatic stem cells for example, mesenchymal stem cells (MSC), hematopoietic stem cells, amniotic cells, umbilical cord blood cells, bone marrow-derived cells, myocardial stem cells, adipose-derived stem cells, or neural stem cells can be used.
- MSC mesenchymal stem cells
- progenitor cells and mature cells include skin, dermis, epidermis, muscle, myocardium, nerve, bone, cartilage, endothelium, brain, epithelium, heart, kidney, liver, pancreas, spleen, oral cavity, cornea, bone marrow, umbilical cord Cells derived from blood, amniotic membrane, or hair can be used.
- human-derived cells examples include ES cells, iPS cells, MSCs, chondrocytes, osteoblasts, osteoprogenitor cells, mesenchymal cells, myoblasts, cardiomyocytes, cardioblasts, neurons, hepatocytes, Beta cells, fibroblasts, corneal endothelial cells, vascular endothelial cells, corneal epithelial cells, amniotic cells, umbilical cord blood cells, bone marrow-derived cells, or hematopoietic stem cells can be used.
- the origin of the cell may be either an autologous cell or an allogeneic cell.
- the use of the calcium phosphate molded body produced by the method for producing a calcium phosphate molded body according to the present invention is not particularly limited, but is preferably a scaffold for regenerative medicine or tissue repair It is a material. The use of the calcium phosphate molded body will be described later in this specification.
- the present invention further provides a calcium phosphate molded body produced by the method for producing a calcium phosphate molded body according to the present invention described in [1] above.
- the calcium phosphate molded body of the present invention has high strength and can be manufactured quickly and with high modeling accuracy.
- the present invention is further a calcium phosphate molded body formed from calcium phosphate, having a hole communicating with the external space, Provided is a calcium phosphate molded article having a specific gravity of 0.7 g / mL or more and / or a porosity of 75% or less by mercury injection method and a water absorption permeation rate of 0.05 mm / second or more.
- the specific gravity of the calcium phosphate molded body is 0.7 g / mL or more, preferably 0.75 g / mL or more, more preferably 0.85 g / mL or more.
- the porosity of the calcium phosphate molded body by the mercury injection method is 75% or less, more preferably 70% or less, still more preferably 67% or less, and particularly preferably 65% or less.
- the mercury intrusion method is a method that uses the high surface tension of mercury to apply pressure to inject mercury into the pores of the powder, and finds the specific surface area and pore distribution from the pressure and the amount of mercury intruded.
- the porosity can be measured using a device such as POREMASTER 60GT (manufactured by Quantachrome).
- the water absorption rate of the calcium phosphate molded body is 0.05 mm / second or more, preferably 0.10 mm / second or more, more preferably 0.30 mm / second or more, and even more preferably 0.50 mm / second. Or more, more preferably 0.70 mm / second or more, still more preferably 0.80 mm / second or more, and particularly preferably 0.90 mm / second or more.
- the water absorption penetration rate of the calcium phosphate molded body only needs to satisfy the above water absorption penetration rate in at least one of the X direction (drawing direction), the Y direction (recoat scanning direction), and the Z direction (stacking direction). However, it preferably satisfies the above water absorption rate in any two of the above directions, and more preferably satisfies the above water absorption rate in all the above directions (three directions).
- the water absorption permeation rate in the present invention is measured under the following conditions.
- the temperature of the laboratory during measurement is kept at 20 to 25 ° C and humidity is kept at 25 to 40%.
- One end of a plastic cylinder with an inner diameter of 2 mm is connected to a calcium phosphate molded body with a diameter of 8 mm and a height of 20 mm, and the other end of the plastic cylinder is connected.
- the height of the area of the calcium phosphate molded body into which the ink penetrated did not reach 15 mm within 5 minutes, the height of the area of the calcium phosphate molded body into which the ink had penetrated was measured with a ruler at the time of 5 minutes. The value divided by the time is taken as the water absorption rate.
- the ratio of the number of Ca / P atoms is preferably 1.4 to 1.8, more preferably 1.45 to 1.79, and still more preferably 1. 50 to 1.70.
- the calcium phosphate molded body of the present invention preferably has a structure in which a relatively dense layer and a relatively sparse layer are alternately laminated.
- the relatively dense layer and the relatively sparse layer are layers that can be identified as a relatively dense layer and a relatively sparse layer by measurement using nanofocus X-ray CT or microfocus X-ray CT. Means.
- a relatively dense layer means denser than a relatively sparse layer, and a relatively sparse layer means sparser than a relatively dense layer. .
- the pattern of the internal structure of the calcium phosphate molded body can be seen, and the relatively dense layer and the relative structure can be seen. Adjust the appearance of white, gray, and black so that sparsely visible layers can be seen.
- the orientation of Ca phosphate is adjusted so that the white and black stripe pattern can be seen, and the direction orthogonal to the white and black stripe pattern is the Z axis, and the direction orthogonal to the Z axis is the XY plane ( The X axis and the Y axis are also orthogonal directions).
- a range of 0.5 mm to 5.0 mm in the Z axis direction and a range of 0.5 mm to 5.0 mm in the X axis direction are selected.
- a waveform can be formed with the distance in the Z-axis direction of the selected area as the horizontal axis and the selected area as the vertical axis as the degree of black and white. From the obtained waveform, the number of layers and the pitch of relatively dense and relatively sparse layers can be analyzed.
- a relatively dense layer of preferably at least 5 layers (more preferably at least 7 layers, more preferably at least 10 layers) and at least 5 layers (more preferably at least 7 layers, More preferably, at least 10 layers or more) relatively sparse layers are alternately laminated.
- the pitch between the first relatively dense layer and the second relatively dense layer adjacent to the first relatively dense layer is preferably 50-300 ⁇ m, more preferably 60 Is 200 ⁇ m, more preferably 70 to 150 ⁇ m.
- a relatively dense layer Due to the presence of a relatively dense layer, the outer shape and the internal structure can be formed, and the entire shape can be maintained because it is replaced while absorbed by the cells.
- the presence of a relatively sparse layer allows cells to invade faster, more extensively, and more. Accordingly, by having a structure in which a relatively dense layer and a relatively sparse layer are alternately stacked, a structure in which a relatively dense layer and a relatively sparse layer are alternately stacked is provided. There is an advantage that cell infiltration becomes easier and tissue regeneration is quicker than a calcium phosphate molded body without.
- a communication hole of about 800 ⁇ m (large: also called a first series of holes), a communication hole of about 20 to about 80 ⁇ m (medium: also called a second communication hole), It is preferable that communication holes (small: also referred to as third communication holes) of about 1 to 10 ⁇ m exist.
- FIG. 30 shows a schematic diagram of a calcium phosphate molded body having the above-described three-stage communication holes, and FIG. 31 shows an SEM image.
- the first communication hole is formed by the design of the 3D printer, the second communication hole is due to the increased fluidity while leaving the powder agglomerated, and the third communication hole is due to the gap between the powders. It is.
- the second communication hole is related to a relatively dense layer and a relatively sparse layer.
- the calcium phosphate molded product of the present invention is preferably a waveform diagram in which the distance in one direction of the molded product is displayed on the horizontal axis and the relative CT intensity is displayed on the vertical axis based on the nanofocus X-ray CT image of the calcium phosphate molded product. It has mountain peaks and valley peaks alternately. Preferably, it has at least 5 or more (more preferably at least 7, more preferably at least 10) peak peaks.
- the pitch between the peak of the first peak and the peak of the second peak adjacent to the peak of the first peak is preferably 50 to 300 ⁇ m, more preferably 60 to 200 ⁇ m, and even more preferably 70. ⁇ 150 ⁇ m.
- the use of the calcium phosphate molded body of the present invention is not particularly limited.
- it can be used as a scaffold for regenerative medicine, a product such as regenerative medicine (a tissue culture culture outside the body), or a tissue repair material, It can be used as a scaffold for regenerative medicine or a tissue repair material.
- the tissue repair material in the present invention is a material that contributes to the formation of tissue in the implanted site by being implanted in a living body, and may or may not contain cells. Good. Moreover, the calcium phosphate molded article of the present invention may or may not contain a component that promotes a biological reaction such as a growth factor or a drug. Furthermore, the calcium phosphate molded body of the present invention may be used by mixing with an inorganic material such as hydroxyapatite, or may be used as a composite with the above inorganic material.
- the tissue repair material in the present invention includes not only a material that contributes to the formation of normal tissue normally present at the site of implantation, but also a material that promotes the formation of non-normal tissue including scar tissue and the like.
- the tissue repair material include, but are not limited to, cartilage, meniscus, skin or bone repair materials. That is, the calcium phosphate molded article of the present invention can be used as a therapeutic agent for regeneration of cartilage, meniscus, skin or bone.
- the disease is not limited, but as an example, diseases involving cartilage defects include osteoarthritis, osteochondral defect, severe osteochondritis, traumatic cartilage damage And osteoarthritis, relapsing polychondritis, achondroplasia, intervertebral disc injury, intervertebral disc herniation and the like.
- the molded article of calcium phosphate of the present invention can be used as a bone regeneration treatment agent in combination with transplanted cells or osteoinductive drugs.
- the osteoinductive agent include BMP (bone forming factor) and bFGF (basic fibroblast growth factor), but are not particularly limited.
- the tissue repair method in the present invention includes applying a tissue repair material, which is a calcium phosphate molded body, to a site where a target tissue is deficient or damaged, and may include other steps as necessary.
- a tissue repair material which is a calcium phosphate molded body
- the transplanted cell and / or the osteoinductive agent may be applied to a site to which the tissue repair material is applied before or after the tissue repair material is applied.
- an incision, an injection, an arthroscope, an endoscope, or the like can be used as a method for applying the calcium phosphate molded article to a site where the target tissue is deficient or damaged.
- the calcium phosphate molded body of the present invention preferably has a hole (first hole) communicating with the external space.
- a hole first hole communicating with the external space.
- the hole communicating with the external space penetrates the inside of the molded body and communicates with the external space at both ends of the hole.
- the average diameter of the holes communicating with the external space is not particularly limited, but is preferably 200 ⁇ m to 2000 ⁇ m.
- the hole (first hole) communicating with the external space indicates that the hole is formed in the space inside the molded body from the surface of one part of the molded body. That is, the space inside the hole communicates with the external space. “The hole communicating with the external space penetrates through the inside of the molded body and communicates with the external space at both ends of the hole” means that the hole extends from the surface of the molded body to the inside of the molded body. It shows that it is formed in a space and communicates with the external space through the surface of another part of the molded body.
- the molded body preferably has, for example, a second hole having a larger average diameter than the first hole as a hole for injecting cells before transplantation. Cells and the like injected from the second hole pass through the first hole and infiltrate the entire molded body.
- the shape of the first hole and the second hole may be any of a circle, a square, a rectangle, a hexagon, an octagon, a cross, and an ellipse.
- the first hole can be provided with an X communication hole, a Y communication hole, and a Z communication hole according to each direction as shown in FIG.
- the communication holes may or may not intersect each other.
- the average diameter of each communicating hole is preferably in the range of 200 ⁇ m to 2000 ⁇ m, and more preferably 200 ⁇ m to 1200 ⁇ m from the viewpoint of easy cell infiltration.
- the average diameter can be measured by, for example, VHX-D510 manufactured by Keyence Corporation.
- the diameter is the distance between two points where the distance between the two points is the largest when taking two points on the outer periphery of the hole when the hole penetrates and is on the outer surface of the molded body. If the hole shape is circular, it means the diameter, and if it is a square, it means the longer of the diagonal lines.
- the average diameter means the sum of the diameters divided by the number of holes when the number of holes is 1 to 4, and the sum of the diameters of 4 is divided by 4 when the number is 5 or more. It shall refer to something.
- the number of first holes communicating with the external space is preferably larger than the number of second holes having an average diameter larger than that of the first holes.
- the molded body may have any shape such as a cube or a rectangular parallelepiped, a cylinder, a triangular cast, and a cone.
- the thickness of the outer edge portion of the structure having no holes is preferably 1.3 mm or more so that the molded body can withstand deformation stress in the body after transplantation (structure strengthening in FIG. 2). region).
- Various external shapes and shapes of complex molded bodies with first and second holes are built on various 3D CAD software on a computer and may be created as unique tailor-made products. It may be created as a standard product with a fixed shape and shape.
- the present invention provides a transplant material including a calcium phosphate molded body in which a part or all of the surface is coated with recombinant gelatin.
- the calcium phosphate molded body is not particularly limited, but preferably, the calcium phosphate molded body having the form described above in the present specification can be used.
- the ratio of the number of Ca / P atoms in the calcium phosphate used for the transplant material is preferably 1.4 to 1.8, more preferably 1.45 to 1.79, and even more preferably 1.50 to 1. .70.
- Details of the recombinant gelatin are as described above in the present specification. Recombinant gelatin is preferably thermally crosslinked or chemically crosslinked.
- the surface of the calcium phosphate compact that is coated with the recombinant gelatin is preferably present on and within the implant material.
- the presence of the surface of the molded article of calcium phosphate coated with the recombinant gelatin on the surface of the implantable material means that the surface of the implantable material is coated with the recombinant gelatin.
- the surface of the calcium phosphate molded body coated with the recombinant gelatin is present inside the transplant material.
- the transplant material, that is, the calcium phosphate molded body is porous, and the pores existing inside the calcium phosphate molded body are removed. It means that the surface to be formed is coated with recombinant gelatin.
- the calcium phosphate molded body is preferably block-shaped or granular.
- the block shape is not limited to a three-dimensional shape composed of only a flat surface, but includes a curved solid body having a curved surface.
- a rectangular parallelepiped shape having a length of 2.0 to 100.0 mm, a width of 2.0 to 100.0 mm, and a height of 2.0 to 100.0 mm can be given.
- Granular means a collection of particles having a particle size of about 0.5 to 2.0 mm.
- Example 1 (1) Method for producing calcium phosphate powder As raw materials for calcium phosphate powder, Ca 4 (PO 4 ) 2 O (tetracalcium phosphate: TTCP) and CaHPO 4 .2H 2 O (calcium hydrogen phosphate dihydrate: DCPD) And were used.
- the ratio of the number of Ca / P atoms in TTCP is 2.0, and the ratio of the number of Ca / P atoms in DCPD is 1.0.
- Table 1 shows the mixing ratio (molar ratio) of TTCP and DCPD and the ratio of the number of Ca / P atoms in the mixed powder at that time.
- a step of forming a layer containing calcium phosphate powder on the substrate, and an organic acid solution is ejected in a droplet state from the nozzle portion to the layer containing calcium phosphate powder.
- the types of calcium phosphate powder and organic acid solution are as shown in Tables 2 and 3.
- the calcium phosphate powder to which the organic acid solution was dropped was allowed to stand for 30 minutes while being kept at about 40 ° C., and then the unnecessary portion of the calcium phosphate powder (calcium phosphate powder not formed with the organic acid solution) was removed with compressed air.
- the removal of unnecessary portions of calcium phosphate powder was evaluated according to the following criteria, and the strength of the calcium phosphate powder was evaluated. Evaluation A indicates that the calcium phosphate molded body has sufficient strength.
- Evaluation A When unnecessary portions can be removed without any problem Evaluation B: When there is a partial breakage in the calcium phosphate powder dropped with the organic acid solution Evaluation C: When the calcium phosphate powder dropped with the organic acid solution collapses
- Results of evaluation Table 2 shows the results of the evaluation when a citric acid solution having a different pH is dropped onto calcium phosphate powder in which the ratio of the number of Ca / P atoms is changed.
- Table 3 shows the results of evaluation in the case where pH 3 solutions of various organic acids were dropped onto calcium phosphate powder having a Ca / P atomic ratio of 1.67.
- the acid citric acid, oxalic acid, tartaric acid, malonic acid
- succinic acid succinic acid (solubility 1) .27) was evaluated as B
- lactic acid, acetic acid and gluconic acid having higher solubility were evaluated as C.
- acids and gluconic acids having a calcium salt solubility in water (g / 100 mL) of 1.0 or less could not be measured due to sample disintegration, resulting in a D determination.
- the solubility of calcium salt of organic acid in water is 1 g / 100 mL or less with respect to calcium phosphate powder having a Ca / P atomic ratio of 1.4 to 1.8, and pH 3.5 It was shown that a good evaluation result can be achieved by discharging and dropping the organic acid solution as described below.
- the particle size ( ⁇ m) when accumulated 10% from the fine side is d10
- the particle size ( ⁇ m) when accumulated 25% from the fine side is d25
- This mixture which was mixed in step (1), was used as Ca phosphate powder.
- LMS-2000e manufactured by Seishin Co., Ltd. was used, and the dispersion medium was measured with ethanol.
- the ink and powder were replaced with Na citrate ink and Ca phosphate powder, and the stacking thickness was 100 ⁇ m, and the design was as shown in FIG.
- four circular one-sided second holes with a diameter of 2 mm were provided, and the non-penetrating end was 9 mm from the outer surface.
- the first hole is a square hole with an average diameter of 900 ⁇ m designed so as to be orthogonal to the X, Y, and Z directions.
- the first hole is an X communication hole, a Y communication hole, and a Z communication hole.
- a suture hole was designed in order to fix and fix the molded body.
- After molding with a 3D printer it was dried in a 3D printer at 35 ° C. for 1 hour, and excess powder was removed with compressed air (air blow flow that produced compressed air adjusted to 0.15 MPa from an air gun).
- the molded body was heated at 100 ° C. per hour in a muffle furnace, then sintered at 1100 ° C. for 2 hours, heating for sintering was turned off, and the lid of the muffle furnace was not opened. Let stand for 8 hours. After the muffle furnace reached a temperature of 100 ° C. or lower, the sintered compact was taken out to obtain a compact (FIG. 4).
- PBS + (in this case, D8662 manufactured by SIGMA-ALDRICH, Inc. was used to evaluate the permeability to the entire molded body.
- PBS is phosphate buffered saline and used in biochemistry and other experiments. It is composed of ions that are universally present in the living body, and has a composition of pH 7.4 and contains NaCl, KCl, Na 2 HPO 4 , KH 2 PO 4, etc.
- the permeability was measured as follows. In a plastic container with a diameter of 55 mm, add 10 mL of the dye-containing PBS + solution to a depth of about 3 mm. The molded body was immersed therein, and it was measured how many seconds after the immersion the entire area of the molded body was colored. As a result, even if the time required for penetrating the entire molded body is 1 hour or longer in the molded body without holes, more than half of the upper surface is not colored. The molded body having only the second hole was colored for 10 minutes, and the molded body having the first hole and the second hole was colored throughout the molded body within 5 seconds. From this result, it was shown that the permeability of the molded body was remarkably high in the molded body having the first hole and the second hole.
- Example 2 Step of Curing Molded Body by Immersion Calcium phosphate powder having a Ca / P atomic ratio of 1.67 produced in (1) of Example 1 was converted into Z-Printer310 Plus (3D Systems Corporation (formerly). Z Corporation)), and using a citric acid solution having a pH of 3, a 5 ⁇ 5 ⁇ 12 mm compact was produced.
- the ratio of the volume of the organic acid solution supplied to the powder unit volume was 42%, and the stacking pitch of the calcium phosphate powder was 100 ⁇ m.
- a step of forming a layer containing calcium phosphate powder on the substrate, and a citric acid solution is ejected in a droplet state from the nozzle portion to the layer containing calcium phosphate powder.
- Solution A 0.5 mol / L sodium dihydrogen phosphate solution (pH 4.3)
- Solution B 0.5 mol / L disodium hydrogen phosphate solution (pH 9)
- Solution C 1: 1 mixed solution of solution A and solution B (pH 6.6)
- Compressive strength was measured using an Electroforce 5500 manufactured by TA Instruments.
- a compressive strength (MPa) was determined by applying a load at a rate of 0.17 mm / second in the longitudinal direction of a 5 ⁇ 5 ⁇ 12 mm sample and dividing the maximum load (N) at the time of sample breakage by the cross-sectional area.
- the compressive strength which was 2.2 MPa before immersion, is 4.2 MPa when immersed in solution A, 3.5 MPa when immersed in solution B, and 3.9 MPa when immersed in solution C. It was. It was confirmed that the molded body was cured by immersing the molded body in the solution, and the strength increased.
- Example 3 Molded Body Curing Step by Heating A calcium phosphate molded body produced in the same manner as in Example 2 was heated at 1100 ° C. or 1200 ° C. for 4 hours using a muffle furnace.
- the compressive strength before and after heating was measured in the same manner as in Example 2.
- the compression strength, which was 2.2 MPa before heating, was 3.5 MPa in the case of heating at 1100 ° C. and 6.1 MPa in the case of heating at 1200 ° C. It was confirmed that the strength was increased by heating the compact.
- the organic acid used for modeling can also be removed by thermal decomposition.
- Example 4 Confirmation of effect of RCP modification on cell adhesion (operation 1) 7.5% (amino acid sequence of SEQ ID NO: 1) at 37 ° C. with bone grafting material Osferion (produced by Olympus Terumo Biomaterial Co., Ltd.) as ⁇ -TCP particles RCP) solution was immersed for 3 hours with shaking. Then, it was dried at 50 ° C. for 12 hours. Further, a thermal crosslinking treatment was performed at 160 ° C. for 20 hours to obtain a preparation. (Operation 2) The prepared preparation was placed in a 24-well ultra-low adhesion plate (Corning) at 10 mg / well, and cells (NIH-3T3) were seeded at 50,000 cells / well. (Operation 3) 24 hours after seeding, after calcein staining, observation with a fluorescence observation and a scanning electron microscope (SEM) was performed.
- Osferion produced by Olympus Terumo Biomaterial Co., Ltd.
- Comparative Example 4 In Example 4, except that the operation 1 was not performed, an example in which the same operation as that of the example 4 was performed was defined as a comparative example 4.
- Example 4 The results of Example 4 and Comparative Example 4 are shown in FIG. In Example 4, the cell adhesion was improved in comparison with Comparative Example 4 (FIG. 5).
- Example 5 Confirmation of effect of RCP modification by bone regeneration induction test in rat parietal bone defect part SD rats (male, 10-12 weeks old, 0.3-0.5 kg) were used as experimental animals to expose the rat parietal bone. A circular bone defect having a diameter of 5 mm was prepared. After filling about 10 mg of the preparation of Example 4 into the prepared bone defect, the skin was sutured. At 8 weeks after implantation, the blood was lethal and the head was removed. Histological observation of the parietal bone including the implantation site was performed by HE staining.
- Comparative Example 5 In Example 5, the same operation was performed as Comparative Example 5 except that the preparation of Comparative Example 4 was used instead of the preparation of Example 4.
- Example 5 The results of Example 5 and Comparative Example 5 are shown in FIG. In Example 5, the bone formation was improved in comparison with Comparative Example 5 (FIG. 6).
- Example 6 Porosity, specific gravity and water absorption rate of calcium phosphate molded body
- the particle size ( ⁇ m) when accumulated 10% from the fine side is d10
- the particle size ( ⁇ m) when accumulated 25% from the fine side is d25
- the mixed Ca phosphate powder contains about 35% of particles having a particle size of 5 to 15 ⁇ m on a volume basis and 32% of particles having a particle size of 25 to 100 ⁇ m.
- LMS-2000e manufactured by Seishin Co., Ltd. was used, and the dispersion medium was measured with ethanol.
- the ink and powder were replaced with Na citrate ink and Ca phosphate powder, and the lamination thickness was 100 ⁇ m.
- the structure was cylindrical, and was shaped with a diameter of 8.8 mm and a height of 22 mm, considering that it would shrink 10% when sintered.
- the porosity was measured by mercury porosimetry.
- the mercury intrusion method is a method that uses the high surface tension of mercury to apply pressure to inject mercury into the pores of the powder, and finds the specific surface area and pore distribution from the pressure and the amount of mercury intruded. It is. It measured using POREMASTER 60GT (made by Quantachrome). The measurement was performed under the following standard conditions. Hg Surface Tension 480.00 erg / cm 2 Hg Contact Angle (I) 141.30 °, (E) 141.30 ° Temperature 20.00 [°C]
- the sample size is a cylindrical shape having a diameter of 0.462 mm and a height of 0.959 mm.
- the syringe 25 used a 10 mL syringe.
- the inner diameter was made larger than that of the calcium phosphate molded body 21.
- the value obtained by dividing 15 mm by the time required for the penetration is the water absorption penetration rate, and the calcium phosphate molded body that the ink has penetrated If the height of the area does not become 15 mm within 5 minutes, measure the height of the area of the calcium phosphate molded body into which the ink penetrated at 5 minutes with a ruler and divide by 5 minutes, the time required for penetration. The value is the water absorption rate.
- Example 7 Density Laminated Structure of Calcium Phosphate Molded Body ⁇ Method for Producing Calcium Phosphate Molded Body>
- the mixed Ca phosphate powder contains about 35% of particles having a particle size of 5 to 15 ⁇ m on a volume basis and 32% of particles having a particle size of 25 to 100 ⁇ m.
- the ink and powder were replaced with Na citrate ink and Ca phosphate powder, and the lamination thickness was 100 ⁇ m.
- the structure is a structure in which three disks are stacked, and the largest disk is a disk having a diameter of 14.4 mm and a total height of 7.8 mm.
- FIG. 8 shows the structure of the object used for the analysis of the sparse / dense laminated structure. Observation and analysis were performed under the following measurement conditions using a phoenix nanotom manufactured by General Electronics. Tube voltage: 120 kV Tube current: 90 ⁇ A Distance from X-ray source to detector (FDD): 600 mm Distance from the X-ray source to the center of rotation of the target sample (FOD): 400 mm Resolution: 6.66 ⁇ m for X, Y and Z axes
- the white, gray, and black appearances are adjusted in the rendering function screen shown in the lower right of Fig. 9.
- the whiter the color the higher the density of the material, and the darker the color, the lower the density of the material. In this case, the whiter the more calcium phosphate, the lower the calcium phosphate, the closer to the void. It will be.
- XY plane, YZ plane, and ZX plane that are geometrically orthogonal to each other are displayed in the area in the VG Studio Max 3.0.3 64bit screen as the XY plane diagram, YZ plane diagram, and ZX plane diagram in FIG.
- VG Studio Max 3.0 is set so that the white stripes and white stripes are aligned as much as possible so that the white and black stripe patterns in the YZ plane and the XZ plane are oriented in the same direction.
- .3 Adjust the orientation of the calcium phosphate compact in 64bit. By this operation, the sparse layer and the dense layer of the sparsely laminated structure of the calcium phosphate molded body become parallel to the XY plane. As shown in FIG. 9, the orientation of the calcium phosphate compact is adjusted, and the direction perpendicular to the white and black stripe pattern is the Z-axis of the calcium phosphate compact.
- a ZX plane image, including the Z axis, is saved on a computer in TIFF format, and is the de facto standard image analysis in the biological imaging field.
- ImageJ 1.50i ImageJ is the National Institutes of Health (NIH) TIFF image data is opened with developed open source and public domain image processing software.
- ImageJ 1.50i select the area of 3.14mm in the Z-axis direction and 3.14mm in the X-axis direction (Fig. 10).
- the images on the ZX plane alternate in the Z direction so as to cross the dense layer and the sparse layer.
- the dense layer extends almost linearly, and the sparse layer also extends almost linearly.
- a distance range of 0.5 mm to 5.0 mm is preferable in the Z-axis direction, and a distance of 2.0 mm to 4.0 mm is more preferable. It is preferable to select a wider area of 2.0 mm or more because it is not affected by the locality of the calcium phosphate molded body, but it is not possible to carry out when the calcium phosphate molded body is small, and therefore it is adjusted appropriately. If it is too large, subsequent work becomes difficult, so 5.0 mm is the upper limit, and 4.0 mm is more preferable.
- the distance in the Z-axis direction of the selected area can be displayed on the horizontal axis
- the black and white level of the selected area can be displayed as a gray value on the vertical axis
- a waveform FIG. 11
- the displayed Gray Value value is an average value of the Gray Value value of each pixel within 3.14 mm of the X axis according to the distance of the Z axis. In this case, it is 153 pixels between 3.14mm.
- a distance range of 0.5 mm to 5.0 mm is preferable in the X-axis direction, and a distance of 2.0 mm to 4.0 mm is more preferable. It is preferable to select a wider area of 2.0 mm or more because it is not affected by the influence of the locality of the calcium phosphate molded body and the resolution of the pixels.
- the calcium phosphate molded body is small, it is not possible to carry out the adjustment. If it is too large, there will be an influence of the orientation of the sparse and dense layers of the calcium phosphate molded body and the coincidence of the X axis, Y axis, and Z axis directions built in VG Studio Max 3.0.3 64 bits. More preferably, the upper limit is 4.0 mm.
- the number of layers and the pitch of the relatively dense layer and the relatively sparse layer are analyzed. Count the number of dense vertices.
- the top of the dense layer is where the density of the material is relatively higher than the surrounding area, and the coefficient of the slope of the waveform changes from positive to negative.
- the apex of the sparse layer is where the material density is relatively smaller than the periphery of the sparse layer, and the slope coefficient of the waveform changes from negative to positive.
- the Z-axis selection distance was 3.14 mm, and there were 34 dense layer vertices between 3.0 mm in the waveform graph formed by the plot profile function.
- (Number of dense layer vertices / Z-axis distance) ZX plane pitch of the densely laminated structure of the calcium phosphate compact. In this case, the pitch is 3.0 mm / 34 and 88.2 ⁇ m (FIG. 11).
- the pitch of the YZ plane (FIG. 12) of the dense and dense laminated structure of the calcium phosphate molded body was derived by the same processing as the view of the XZ plane.
- (Number of dense layer apexes / Z-axis distance) YZ plane pitch of the densely laminated structure of the calcium phosphate compact. This case is 3.0mm / 32 pieces, and 93.8 ⁇ m pitch (Fig. 13)
- the average of the pitch on the ZX plane of the densely laminated structure of the calcium phosphate molded body and the pitch on the YZ plane of the densely laminated structure of the calcium phosphate molded body is taken as the pitch of the densely laminated structure of the calcium phosphate molded body.
- the gap of the sparse layer extends from several millimeters to several tens of millimeters, and is not a bent three-dimensional connection, but a simple, straight, planar connection, and further, one surface of the calcium phosphate molded body faces the other. It is considered that the penetrating ink permeates without receiving the air resistance due to the fact that it has fallen on both sides to the other surface.
- Example 8 Laser diffraction particle size distribution measurement of calcium phosphate powder As calcium phosphate powder, Ca 4 (PO 4 ) 2 O (tetracalcium phosphate: TTCP), CaHPO 4 .2H 2 O (calcium hydrogen phosphate dihydrate: DCPD) and a mixed powder of TTCP and DCPD (Ca / P atomic ratio is 1.5), the particle size distribution was measured by the following method and conditions.
- Measurement principle Particles dispersed in a dispersion medium such as water or ethanol are irradiated with laser light, and the particle size distribution of the particles contained in the sample is obtained by measuring the angle dependence of the intensity of scattered light from the particles. Measurement range: 0.02 to 2000 ⁇ m Laser light source: Helium neon laser Dispersion medium: Ethanol Measurement method: After performing a blank measurement with only the dispersion medium, the sample is dispersed by ultrasonic dispersion for 1 minute, and the ultrasonically dispersed sample is placed in a dispersion tank and circulated. Measure particle size distribution. Particle size distribution: Displayed on a volume basis.
- FIG. 14 shows the measurement result of the mixed powder
- FIG. 15 shows the measurement result of the TTCP powder
- FIG. 16 shows the measurement result of the DCPD powder.
- the particle size ( ⁇ m) when accumulated 10% from the fine side is d10
- the particle size ( ⁇ m) when accumulated 25% from the fine side is d25
- the particle when accumulated 50% from the fine side is expressed as d50
- the particle diameter ( ⁇ m) when 75% is accumulated from the fine side as d75
- TTCP is The d50 corresponding to the median diameter is 7.4 ⁇ m
- This mixture which was mixed in step (1), was used as Ca phosphate powder.
- the fluidity (flow function) of the above powder was measured by the following method. As a measuring device, a “powder flow tester, PFT” manufactured by Brookfield was used to select and measure the standard flow function. When the fracture strength was fc and the maximum principal stress was ⁇ 1, ⁇ 1 / It is a value represented by fc. The flow function value was evaluated according to the following criteria.
- TTCP has poor fluidity, and when the powder is recoated only with TTCP, TTCP adheres to the roller or is visible on the surface of the TTCP powder that should have become flat. There are irregularities of several mm or more. ⁇ When DCPD is mixed, the mixed powder does not adhere to the roller, and the surface of the mixed powder can be recoated without unevenness.
- TTCP powder has high reactivity with organic acid solutions and is suitable for 3D powder lamination printer modeling from the viewpoint of reactivity.
- the flowability is less than 4.0 in the flow function, and recoat failure occurs.
- the fluidity is related to the particle size, and if the particle size is small, the fluidity deteriorates. The smaller the particle size, the larger the specific surface area, the more the surface is affected than the volume proportional to the mass, the van der Waals force acting on the surface of the powder particle adjacent to the surface of a certain powder particle, static electricity The effect of attractive force that attracts particles, such as force, is significant.
- d50 17.0 ⁇ m, and even if about 35% of particles having a particle size of 5 to 15 ⁇ m are contained on a volume basis, the effect of containing 32% of particles having a particle size of 25 to 100 ⁇ m is affected.
- the flow function value was 3.34, but the mixed powder was 4.87, which is close to the value of 5.13 in DCPD alone. As a result, no recoating failure occurs and 3D powder lamination printing can be performed.
- the particle size ( ⁇ m) when accumulated 10% from the fine side is d10
- the particle size ( ⁇ m) when accumulated 25% from the fine side is d25
- the mixed Ca phosphate powder contains about 35% of particles having a particle size of 5 to 15 ⁇ m on a volume basis and 32% of particles having a particle size of 25 to 100 ⁇ m.
- the ink and powder were replaced with Na citrate ink and Ca phosphate powder, and the lamination thickness was set to 100 ⁇ m.
- FIG. 1 A schematic diagram of the calcium phosphate compact is shown in FIG.
- the structure is a disk with a diameter of 5 mm and a height of 1.9 mm.
- a 0.7 ⁇ 1.0 m communicating hole is formed in a cross shape in the X direction and the Y direction at a height about the middle of the disk in parallel with the bottom surface of the disk.
- -A communication hole with a diameter of 1.1 mm is formed in the Z-axis direction so as to penetrate the center of the cross shape.
- a convex portion having a width of 1.8 mm and a height of 0.4 mm is formed on the upper surface side of the disk on the communication hole and the upper side in the X direction and the Y direction.
- the molded body is coated with CBE3.
- the method for preparing the CBE3 aqueous solution and the coating of CBE3 with Ca phosphate are as follows. 7% by mass of CBE3 was dissolved in an aqueous injection solution manufactured by Hikari Pharmaceutical Co., Ltd., heated in an oven at 45 ° C. for 30 minutes, and dissolved to prepare a CBE3 aqueous solution.
- the calcium phosphate compact is immersed in an aqueous solution of CBE3 and vacuum degassed in a desiccator from atmospheric pressure to -0.09 MPa, and air is dissolved in the aqueous solution or air from the voids inside the Ca phosphate compact. Leave for 10 minutes while removing.
- a defect with a diameter of 5 mm was provided and the test material was placed. After the peeled periosteum was applied, the skin was sutured.
- Microfocus CT analysis was performed for test A (control: defect only).
- Microfocus CT is an R-mCT manufactured by Rigaku Corporation.
- the tube voltage is 90 kV
- the tube current is 100 ⁇ A
- the X-ray focus-detector distance (FDD) is 292 mm
- the X-ray focus-rotation center distance (FOD). ) Is 73 mm.
- the analysis result of microfocus CT is shown in FIG.
- the control shows bone regeneration from the outer periphery of the existing bone, but does not show regeneration that compensates for the rat head defect.
- FIG. 19 shows the results of micro CT analysis of test B (CBE3-coated Ca phosphate molded body (molded body B)) 8 weeks after transplantation into rats. Sufficient bone healing can be confirmed where the molded body B and the rat's own bone are in contact. Both the external shape of the molded body B and the internal structure formed by the 3D printer are maintained.
- FIG. 20 shows the results of micro CT analysis of the transplanted molded body B every 0 to 2 weeks. After 4 weeks, it can be confirmed that bones are newly formed in the cross-shaped communication holes of about 0.7 ⁇ 1.0 mm that are designed and created, and have grown after 6 weeks.
- FIG. 21 shows the result of micro CT analysis of the transplanted molded product B after 8 weeks.
- the analysis conditions are the same as in Test A above. Bone is born in the communication hole of about 0.7 ⁇ 1.0 mm created by design and grows to 3.5 mm at a long place. Moreover, it can also be confirmed by the pathological specimen and von Kossa staining that what is formed inside the communication hole is definitely a bone.
- FIG. 22 shows the results of pathological specimen and H & E staining after 8 weeks of the transplanted molded product B.
- the pathological specimen in FIG. 22 is close to the pathological specimen in FIG. It can be seen that cells are infiltrated into a soft tissue even in the vicinity of a new bone inside a cross-shaped communicating hole of 0.7 ⁇ 1.0 mm created by 3D printing design. When laminating 3D printed powder, cells infiltrate into the loose layer (about 20 to 80 ⁇ m) of the loosely formed densely laminated structure, which is a soft tissue.
- FIG. 23 and FIG. 24 show the results of the pathological specimen and H & E staining of the transplanted molded body B after 8 weeks from a rat (second animal) different from the above.
- Angiogenesis was confirmed inside the 0.7 ⁇ 1.0 mm communicating hole created by 3D printing design. ⁇ New blood vessels were confirmed both in the sparse layer of the sparsely laminated structure (about 20-80um) that was autonomously formed during 3D powder lamination printing.
- FIG. 25 shows the pathological specimen of rat (third) different from the above, and the result of von von Kossa staining for the transplanted molded product B. It can be confirmed that calcium phosphate is absorbed and replaced by bone.
- the particle size ( ⁇ m) when accumulated 10% from the fine side is d10
- the particle size ( ⁇ m) when accumulated 25% from the fine side is d25
- the mixed Ca phosphate powder contains about 35% of particles having a particle size of 5 to 15 ⁇ m on a volume basis and 32% of particles having a particle size of 25 to 100 ⁇ m.
- LMS-2000e manufactured by Seishin Enterprise Co., Ltd. was used, and the dispersion medium was measured with ethanol.
- the coating amount of the organic acid solution is a three-dimensional design of 1 cm 3 with respect to the plastic container in which the calcium phosphate molded body is originally formed by removing the calcium phosphate powder from the 3D printer and measuring the weight of the plastic container.
- An organic acid solution for forming an object is discharged, the weight of the plastic container is measured with the organic acid solution placed thereon, and the weight of the discharged organic acid solution is measured.
- 1.0 mol / L sodium citrate aqueous solution is tested in the range of 0.12 g / 1 cm 3 to 0.38 g / 1 cm 3 , and 1.0 mol / L sodium citrate aqueous solution is in the range of 0.215 g / 1 cm 3 to 0.29 g / 1 cm 3 . Tested.
- the powder and the aqueous sodium citrate solution were introduced into Z-Printer310 Plus (3D Systems Corporation (former Z Corporation)) to create a 20 ⁇ 20 ⁇ 8 mm rectangular parallelepiped.
- the ink and powder were replaced with Na citrate ink and Ca phosphate powder, and the lamination thickness was set to 100 ⁇ m.
- the compressive strength was measured using a digital force gauge ZTA-1000N manufactured by Imada Corporation in the same manner as the vertical electric measurement stand MX2 manufactured by Imada Corporation. Approximately 18 x 18 x 7.2 mm A sample was loaded at a speed of 0.17 mm / sec in the longitudinal direction of the sample, the shape of the sample was accurately measured with calipers, and the maximum load (N) at the time of sample breakage was measured in cross-sectional area. The compressive strength (MPa) was determined by dividing. The evaluation of the warpage of the bottom surface was performed according to the following criteria. A sample of classes 1 to 5 is shown in FIG.
- FIG. 27 shows the relationship between the coating amount and the compressive strength of the calcium phosphate molded body produced using the 1.0 mol / L sodium citrate aqueous solution or the 1.2 mol / L sodium citrate aqueous solution, and the relationship between the coating amount and the warp of the bottom surface.
- FIG. 28 shows the relationship between the compressive strength and the warp of the bottom surface.
- FIG. 27 shows the relationship between the compressive strength and the warping of the bottom surface, integrating the relationship between the coating amount and the compressive strength of FIG. 27 and the relationship between the coating amount and the warping of the bottom surface of FIG. It can be clearly seen that the relationship is off.
Abstract
Description
<1> Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を含有する層を基板上に形成する工程a;及び
有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液をノズル部から液滴状態で吐出させて、上記有機酸溶液を上記工程aで形成したリン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程b;
を含む、リン酸カルシウム成形体の製造方法。
<2> 上記工程bで使用する有機酸が、クエン酸、シュウ酸、酒石酸、マロン酸及びリンゴ酸からなる群から選択される少なくとも1種である、<1>に記載のリン酸カルシウム成形体の製造方法。
<3> 上記工程bの後に、
Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を含有する層を、上記工程aで形成したリン酸カルシウム粉末を含有する層の上に形成する工程c;及び
有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液をノズル部から液滴状態で吐出させて、上記有機酸溶液を上記工程cで形成したリン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程d;
をさらに含む、<1>又は<2>に記載のリン酸カルシウム成形体の製造方法。
<4> 上記工程dで使用する有機酸が、クエン酸、シュウ酸、酒石酸、マロン酸及びリンゴ酸からなる群から選択される少なくとも1種である、<3>に記載のリン酸カルシウム成形体の製造方法。
第一のリン酸カルシウム粉末と第二のリン酸カルシウム粉末とを含む上記リン酸カルシウム粉末は、粒子径5~15μmの粒子と、粒子径25~100μmの粒子とを少なくとも含み、粒子径25μm以上の粒子を体積基準で20%以上含む、<1>から<4>の何れか一に記載のリン酸カルシウム成形体の製造方法。
<6> 第一のリン酸カルシウム粉末のフローファンクションが4.00未満であり、
第一のリン酸カルシウム粉末と第二のリン酸カルシウム粉末とを含む上記リン酸カルシウム粉末のフローファンクションが4.00以上である、<5>に記載のリン酸カルシウム成形体の製造方法:但し、フローファンクションは、破壊強度をfc、最大主応力をσ1とした時、σ1/fcで表される。
<7> 工程bおよび/又は工程dにおける有機酸溶液の濃度が1.1mol/L以上1.4mol/L以下である、<1>から<6>の何れか一に記載のリン酸カルシウム成形体の製造方法。
<8> 工程bおよび/又は工程dにおける有機酸が、クエン酸である、<7>に記載のリン酸カルシウム成形体の製造方法。
<9> 工程bおよび/又は工程dにおける有機酸溶液の塗布量が、0.20g/cm3以上0.30g/cm3以下である、<7>又は<8>に記載のリン酸カルシウム成形体の製造方法。
<10> 工程bおよび/又は工程dにおける有機酸溶液のpHが、2.5以上3.5以下である、<1>から<9>の何れか一に記載のリン酸カルシウム成形体の製造方法。
<12> 上記工程eの後、成形体を水溶液に浸漬することにより成形体を硬化させる工程f、及び/又は成形体を加熱することにより成形体を硬化させる工程gを含む、<11>に記載のリン酸カルシウム成形体の製造方法。
<13> 成形体に生体親和性高分子を被覆する工程hをさらに含む、<1>から<12>のいずれか一に記載のリン酸カルシウム成形体の製造方法。
<14> 上記生体親和性高分子が、リコンビナントゼラチンである、<13>に記載のリン酸カルシウム成形体の製造方法。
<15> 上記工程hの後に、上記生体親和性高分子に細胞を播種する工程iをさらに含む、<13>又は<14>に記載のリン酸カルシウム成形体の製造方法。
<16> リン酸カルシウム成形体が、再生医療用足場材又は組織修復材である、<1>から<15>のいずれか一に記載のリン酸カルシウム成形体の製造方法。
<18> 再生医療用足場材又は組織修復材である、<17>に記載のリン酸カルシウム成形体。
<19> 外部空間と連通している孔を有している、<17>又は<18>に記載のリン酸カルシウム成形体。
<20> 外部空間と連通している孔が、成形体の内部を貫通し、孔の両端において外部空間と連通している、<19>に記載のリン酸カルシウム成形体。
<21> 外部空間と連通している孔の平均径が200μm~2000μmである、<19>又は<20>に記載のリン酸カルシウム成形体。
<22> Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウムから形成されるリン酸カルシウム成形体であって、外部空間と連通している第一の孔及び当該第一の孔よりも平均径が大きい第二の孔を有する、リン酸カルシウム成形体。
<23> 外部空間と連通している第一の孔の平均径が200μm~2000μmである、<22>に記載のリン酸カルシウム成形体。
<24> 外部空間と連通している第一の孔の数が、第一の孔よりも平均径が大きい第二の孔の数よりも多い、<22>又は<23>に記載のリン酸カルシウム成形体。
<26> 上記リン酸カルシウムのCa/Pの原子数の比が1.4~1.8である、<25>に記載の移植用材料。
<27> リコンビナントペプチドが、熱架橋又は化学架橋されている、<25>又は<26>に記載の移植用材料。
<28> リコンビナントペプチドでコートされているリン酸カルシウム成形体の表面が、移植用材料の表面および内部に存在する、<25>から<27>の何れか一に記載の移植用材料。
<29> リン酸カルシウム成形体が、ブロック状である、<25>から<28>の何れか一に記載の移植用材料。
<30> リン酸カルシウム成形体が、顆粒状である、<25>から<28>の何れか一に記載の移植用材料。
外部空間と連通している孔を有し、
比重が0.7g/mL以上であるか、および/又は水銀注入法による気孔率が75%以下であり、
吸水浸透速度が、0.05mm/秒以上である、
リン酸カルシウム成形体;
但し、吸水浸透速度とは、以下の条件で測定したものである。直径8mm高さ20mmのリン酸カルシウム成形体に、内径2mmのプラスチック筒の一端を連結し、上記プラスチック筒の他端を長さ100mmのチューブの一端に連結し、上記チューブの他端を10mLのシリンジに連結した実験系を構築する。リン酸カルシウム成形体とプラスチック筒の接する高さと、シリンジ内のインキの水位の高さとが吸水浸透の開始から終了まで同じになるように調整した条件下において、シリンジ内のインキをリン酸カルシウム成形体に吸水浸透させる。インキが浸透したリン酸カルシウム成形体の領域の高さが5分以内に15mmとなったときは、15mmを浸透に要した時間で割った値を吸水浸透速度とし、インキが浸透したリン酸カルシウム成形体の領域の高さが5分以内に15mmとならない場合は、5分の時点においてインキが浸透したリン酸カルシウム成形体の領域の高さを、浸透に要した時間である5分で割った値を、吸水浸透速度とする。
<32> 上記リン酸カルシウムのCa/Pの原子数の比が1.4~1.8である、<31>に記載のリン酸カルシウム成形体。
<33> ナノフォーカスX線CT又はマイクロフォーカスX線CTによる測定により判別される相対的に密な層と相対的に疎な層とが交互に積層された構造を有している、<31>又は<32>に記載のリン酸カルシウム成形体。
<34> 少なくとも5層以上の相対的に密な層と、少なくとも5層以上の相対的に疎な層とが交互に積層されている、<33>に記載のリン酸カルシウム成形体。
<35> 第一の相対的に密な層と、上記第一の相対的に密な層の隣の第二の相対的に密な層とのピッチが50~300μmである、<33>又は<34>に記載のリン酸カルシウム成形体。
<36> リン酸カルシウム成形体のナノフォーカスX線CT画像に基づいて、成形体の一方向の距離を横軸に、相対CT強度を縦軸に表示した波形図において、山のピークと谷のピークとを交互に有する、<31>又は<32>に記載のリン酸カルシウム成形体。
<37> 少なくとも5つ以上の山のピークを有する、<36>に記載のリン酸カルシウム成形体。
<38> 第一の山のピークと、上記第一の山のピークの隣の第二の山のピークとのピッチが50~300μmである、<36>又は<37>に記載のリン酸カルシウム成形体。
以下に記載する構成要件の説明は、本発明の代表的な実施態様に基づいてなされることがあるが、本発明はそのような実施態様に限定されるものではない。
なお、本明細書において、「~」を用いて表される数値範囲は、「~」の前後に記載される数値を下限値および上限値として含む範囲を意味する。
本発明によるリン酸カルシウム成形体の製造方法は、
Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を含有する層を基板上に形成する工程a;及び
有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液をノズル部から液滴状態で吐出させて、上記有機酸溶液を上記工程aで形成したリン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程b;
を含む。
本明細書で言う「高い強度を有するリン酸カルシウム成形体」とは、リン酸カルシウム成形体が、成形後の取り扱い(例えば、成形体を装置から取り出する操作など)に耐えうる程度の強度を有していることを意味する。
本発明で使用するリン酸カルシウム粉末におけるリン酸カルシウムにおいては、Ca/Pの原子数の比が1.4~1.8である。Ca/Pの原子数の比は、好ましくは1.45~1.79であり、より好ましくは1.50~1.70である。
Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末の製造方法は特に限定されないが、例えば、Ca/Pの原子数の比が既知である2種類以上のリン酸カルシウム粉末を原料として使用し、Ca/Pの原子数の比が1.4~1.8となるように、上記2種類以上のリン酸カルシウム粉末を所定の比率で混合することにより、Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を製造することができる。一例としては、リン酸カルシウム粉末の原料として、Ca4(PO4)2O(リン酸四カルシウム:TTCPとも言う:Ca/Pの原子数の比は2.0)と、CaHPO4・2H2O(リン酸水素カルシウム二水和物:DCPDとも言う:Ca/Pの原子数の比は1.0)とを用いて、TTCPとDCPDとの混合比率を変化させることにより、Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を製造することができる。
好ましくは、第一のリン酸カルシウム粉末と第二のリン酸カルシウム粉末とを含む上記のリン酸カルシウム粉末は、粒子径5~15μmの粒子と、粒子径25~100μmの粒子とを少なくとも含み、粒子径5~15μmの粒子を体積基準で5.0%以上(より好ましくは10%以上、さらに好ましくは15%以上含む)、粒子径25μm以上の粒子を体積基準で20%以上(より好ましくは25%以上、さらに好ましくは30%以上)含む。
本発明における工程aは、リン酸カルシウム粉末を含有する層を基板上に形成する工程である。
基板の材質、形状、及び大きさは、特に限定されず、目的に応じて適切な基板を使用することができる。基板としては、所定の面積の平面を有する基板が好ましい。基板の表面積は特に限定されないが、好ましくは5~200cm2であり、より好ましくは20~100cm2である。
本発明においては、有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液を使用する。有機酸のカルシウム塩の溶解度は、温度25℃における溶解度を意味する。
有機酸溶液について、有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であればよいが、好ましくは0.5g/100mL以下であり、より好ましくは0.1g/100mL以下である。
上記の溶解度を満たす有機酸としては、クエン酸、シュウ酸、酒石酸、マロン酸及びリンゴ酸からなる群から選択される少なくとも1種であることが好ましく、クエン酸、シュウ酸又は酒石酸がより好ましく、クエン酸がさらに好ましい。
pH3.5以下である有機酸溶液は、有機酸及び有機酸の塩(有機酸のナトリウム塩など)の混合比を調整することにより、製造することができる。
有機酸溶液における有機酸の濃度は、特に限定されないが、一般的には0.1mol/L以上5.0mol/L以下であり、好ましくは0.5mol/L以上3.0mol/L以下であり、より好ましくは1.0mol/L以上2.0mol/L以下であり、さらに好ましくは1.1mol/L以上1.4mol/L以下である。
本発明においては、有機酸溶液をノズル部から液滴状態で吐出させて、上記有機酸溶液を工程aで形成したリン酸カルシウム粉末を含有する層に対して滴下させることにより、リン酸カルシウム成形体を製造する。
本発明によるリン酸カルシウム成形体の製造方法は、上記の工程bの後に、
Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を含有する層を、工程aで形成したリン酸カルシウム粉末を含有する層の上に形成する工程c;及び有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液をノズル部から液滴状態で吐出させて、上記の有機酸溶液を工程cで形成したリン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程d;
をさらに含んでいてもよい。
上記の工程dは、工程bと同様に行うことができる。工程dで使用する材料の種類は、工程bと同一でもよいし、異なっていてもよいが、好ましくは同一である。
工程dで使用する有機酸は、工程bの場合と同様に、クエン酸、シュウ酸、酒石酸、マロン酸及びリンゴ酸からなる群から選択される少なくとも1種であることが好ましく、クエン酸、シュウ酸又は酒石酸がより好ましく、クエン酸がさらに好ましい。
工程bおよび/又は工程dにおける有機酸溶液の塗布量は、一般的には0.10g/cm3以上0.40g/cm3以下であり、好ましくは、0.20g/cm3以上0.30g/cm3以下である。
本発明においては、成形体の形成に使用されなかったリン酸カルシウム粉末を除去する工程eをさらに設けることができる。リン酸カルシウム粉末を除去するとは、リン酸カルシウム粉末を、成形体の表面から除去することである。
成形体の形成に使用されなかったリン酸カルシウム粉末を除去することによって、所望の形状に成形された成形体を回収することができる。なお、本発明においては、形成された成形体が所定の強度を有していることにより、成形体を破損することなく、成形体の形成に使用されなかったリン酸カルシウム粉末を除去することができる。
本発明においては、成形体の形成に使用されなかったリン酸カルシウム粉末を除去する工程eの後に、成形体を水溶液に浸漬することにより成形体を硬化させる工程f、及び/又は成形体を加熱することにより成形体を硬化させる工程gをさらに設けることができる。但し、工程f及び工程gはそれぞれ設けてもよいし、設けなくてもよい。
上記の工程f及び/又は工程gを行うことにより、添加した有機酸を除去することができ、成形体の強度を更に高めることができる。
成形体を水溶液に浸漬する時間は、特に限定されないが、一般的には1時間から48時間であり、好ましくは2時間から24時間であり、より好ましくは4時間から24時間である。
加熱は、マッフル炉などを用いて常法により行うことができる。
本発明においては、成形体に生体親和性高分子を被覆する工程hをさらに設けることができる。但し、工程hは設けてもよいし、設けなくてもよい。成形体を生体親和性高分子で被覆することにより、細胞を吸着させ易くすることができる。好ましくは、本明細書で上記したような成形体を硬化させる工程f及び/又は工程gを行うことにより酸を成形体から除去した後に、成形体に生体親和性高分子(好ましくは、後記するリコンビナントゼラチン)を被覆することにより、生体親和性高分子と酸との反応を防止することができる。即ち、本発明の好ましい態様においては、成形体を硬化させる工程f及び/又は工程gを行った後に、成形体に生体親和性高分子を被覆する工程hを行うことができる。
生体親和性とは、生体に接触した際に、長期的かつ慢性的な炎症反応などのような顕著な有害反応を惹起しないことを意味する。生体親和性高分子は、生体に親和性を有するものであれば、生体内で分解されるか否かは特に限定されないが、生分解性高分子であることが好ましい。非生分解性材料として具体的には、ポリテトラフルオロエチレン(PTFE)、ポリウレタン、ポリプロピレン、ポリエステル、塩化ビニル、ポリカーボネート、アクリル、ステンレス、チタン、シリコーン、及びMPC(2-メタクリロイルオキシエチルホスホリルコリン)などが挙げられる。生分解性材料としては、具体的には、天然由来のペプチド、リコンビナントペプチド(RCP)又は化学合成ペプチドなどのポリペプチド(例えば、以下に説明するゼラチン等)、ポリ乳酸、ポリグリコール酸、乳酸・グリコール酸コポリマー(PLGA)、ヒアルロン酸、グリコサミノグリカン、プロテオグリカン、コンドロイチン、セルロース、アガロース、カルボキシメチルセルロース、キチン、及びキトサンなどが挙げられる。上記の中でも、リコンビナントペプチドが特に好ましい。これら生体親和性高分子には細胞接着性を高める工夫がなされていてもよい。具体的には、「基材表面に対する細胞接着基質(フィブロネクチン、ビトロネクチン、ラミニン)や細胞接着配列(アミノ酸一文字表記で現わされる、RGD配列、LDV配列、REDV配列、YIGSR配列、PDSGR配列、RYVVLPR配列、LGTIPG配列、RNIAEIIKDI配列、IKVAV配列、LRE配列、DGEA配列、及びHAV配列)ペプチドによるコーティング」、「基材表面のアミノ化、カチオン化」、又は「基材表面のプラズマ処理、コロナ放電による親水性処理」といった方法を使用できる。
リコンビナントゼラチンについては、本明細書中後記する。
生体親和性高分子は、架橋されているものでもよいし、架橋されていないものでもよい。一般的な架橋方法としては、熱架橋、アルデヒド類(例えば、ホルムアルデヒド、グルタルアルデヒドなど)による架橋、縮合剤(カルボジイミド、シアナミドなど)による架橋、酵素架橋、光架橋、紫外線架橋、疎水性相互作用、水素結合、イオン性相互作用などが知られており、本発明においても上記の架橋方法を使用することができる。本発明で使用する架橋方法としては、さらに好ましくは熱架橋、紫外線架橋、又は酵素架橋であり、特に好ましくは熱架橋である。
本発明で用いるゼラチンとしては、リコンビナントゼラチンが好ましい。
リコンビナントゼラチンとは、遺伝子組み換え技術により作られたゼラチン類似のアミノ酸配列を有するポリペプチドもしくは蛋白様物質を意味する。本発明で用いることができるリコンビナントゼラチンは、コラーゲンに特徴的なGly-X-Yで示される配列(X及びYはそれぞれ独立にアミノ酸の何れかを示す)の繰り返しを有するものが好ましい。ここで、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよい。好ましくは、細胞接着シグナルが一分子中に2配列以上含まれている。本発明で用いるリコンビナントゼラチンとしては、コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンを用いることができる。例えばEP1014176、米国特許6992172号、国際公開WO2004/85473、国際公開WO2008/103041等に記載のものを用いることができるが、これらに限定されるものではない。本発明で用いるリコンビナントゼラチンとして好ましいものは、以下の態様のリコンビナントゼラチンである。
任意のアミノ酸(好ましくは、グリシン以外の任意のアミノ酸)を表す。コラーゲンに特徴的なGly-X-Yで示される配列とは、ゼラチン及びコラーゲンのアミノ酸組成及び配列における、他のタンパク質と比較して非常に特異的な部分構造である。この部分においてはグリシンが全体の約3分の1を占め、アミノ酸配列では3個に1個の繰り返しとなっている。グリシンは最も簡単なアミノ酸であり、分子鎖の配置への束縛も少なく、ゲル化に際してのヘリックス構造の再生に大きく寄与している。X及びYで表されるアミノ酸はイミノ酸(プロリン、オキシプロリン)が多く含まれ、全体の10%~45%を占めることが好ましい。好ましくは、リコンビナントゼラチンの配列の80%以上、更に好ましくは95%以上、最も好ましくは99%以上のアミノ酸が、Gly-X-Yの繰り返し構造である。
この最小アミノ酸配列の含有量は、細胞接着及び増殖性の観点から、タンパク質1分子中3~50個が好ましく、さらに好ましくは4~30個、特に好ましくは5~20個である。最も好ましくは12個である。
好ましくは、リコンビナントゼラチンはテロペプタイドを有さない。
好ましくは、リコンビナントゼラチンは、アミノ酸配列をコードする核酸により調製された実質的に純粋なポリペプチドである。
(1)配列番号1に記載のアミノ酸配列からなるペプチド;
(2)配列番号1に記載のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなり、かつ生体親和性を有するペプチド;又は
(3)配列番号1に記載のアミノ酸配列と80%以上(さらに好ましくは90%以上、特に好ましくは95%以上、最も好ましくは98%以上)の配列同一性を有するアミノ酸配列からなり、かつ生体親和性を有するペプチド;の何れかである。
%配列同一性=[(同一残基数)/(アラインメント長)]×100
2つのアミノ酸配列における配列同一性は当業者に公知の任意の方法で決定することができ、BLAST((Basic Local Alignment Search Tool))プログラム(J.Mol.Biol.215:403-410,1990)等を使用して決定することができる。
成形体に生体親和性高分子を被覆する方法は、特に限定されないが、生体親和性高分子溶液を使用することができる。生体親和性高分子溶液に使用する溶媒は、生体親和性高分子を溶解できる溶媒であれば、特に限定されないが、一般的には、水、有機溶媒、又は水と有機溶媒の混合物であり、好ましくは水、又は水と有機溶媒の混合物などの水性媒体である。有機溶媒としては、例えば、アセトン、エタノール等があげられる。ゼラチン溶液の場合には、好ましくは、ゼラチン水溶液を使用することができる。
本発明においては、上記した成形体に生体親和性高分子を被覆する工程hの後に、生体親和性高分子に細胞を播種する工程iをさらに設けることができる。
本発明における成形体の用途は、後記の通り、再生医療用足場材又は組織修復材などが意図されるが、成形体に細胞を播種して使用する場合と、成形体に細胞を播種せずに使用する場合とが想定される。
使用する細胞として、好ましくは、動物細胞であり、より好ましくは脊椎動物由来細胞、特に好ましくはヒト由来細胞である。脊椎動物由来細胞(特に、ヒト由来細胞)の種類は、万能細胞、体性幹細胞、前駆細胞、又は成熟細胞の何れでもよい。万能細胞としては、例えば、胚性幹(ES)細胞、生殖幹(GS)細胞、又は人工多能性幹(iPS)細胞を使用することができる。体性幹細胞としては、例えば、間葉系幹細胞(MSC)、造血幹細胞、羊膜細胞、臍帯血細胞、骨髄由来細胞、心筋幹細胞、脂肪由来幹細胞、又は神経幹細胞を使用することができる。前駆細胞及び成熟細胞としては、例えば、皮膚、真皮、表皮、筋肉、心筋、神経、骨、軟骨、内皮、脳、上皮、心臓、腎臓、肝臓、膵臓、脾臓、口腔内、角膜、骨髄、臍帯血、羊膜、又は毛に由来する細胞を使用することができる。ヒト由来細胞としては、例えば、ES細胞、iPS細胞、MSC、軟骨細胞、骨芽細胞、骨芽前駆細胞、間充織細胞、筋芽細胞、心筋細胞、心筋芽細胞、神経細胞、肝細胞、ベータ細胞、線維芽細胞、角膜内皮細胞、血管内皮細胞、角膜上皮細胞、羊膜細胞、臍帯血細胞、骨髄由来細胞、又は造血幹細胞を使用することができる。また、細胞の由来は、自家細胞又は他家細胞の何れでも構わない。
本発明によるリン酸カルシウム成形体の製造方法で製造されるリン酸カルシウム成形体の用途は特に限定されないが、好ましくは再生医療用足場材又は組織修復材である。リン酸カルシウム成形体の用途については本明細書中において後記する。
本発明はさらに、上記[1]に記載した本発明によるリン酸カルシウム成形体の製造方法により製造されるリン酸カルシウム成形体を提供する。
本発明のリン酸カルシウム成形体は、高い強度を有し、かつ迅速かつ高い造形精度で製造することができる。
比重が0.7g/mL以上であるか、および/又は水銀注入法による気孔率が75%以下であり、吸水浸透速度が、0.05mm/秒以上である、リン酸カルシウム成形体を提供する。
水銀圧入法とは、水銀の表面張力が大きいことを利用して粉体の細孔に水銀を浸入させるために圧力を加え、圧力と圧入された水銀量から比表面積や細孔分布を求める方法であり、気孔率はPOREMASTER 60GT(Quantachrome社製)等の装置を使用して測定することができる。
リン酸カルシウム成形体の吸水浸透速度は、X方向(描画方向)、Y方向(リコート走査方向)及びZ方向(積層方向)のうちの少なくとも一つの方向において、上記の吸水浸透速度を満たしていればよいが、好ましくは上記のうちの何れか二つの方向において上記の吸水浸透速度を満たし、より好ましくは上記の全方向(三方向)において上記の吸水浸透速度を満たしている。
第一の相対的に密な層と、上記第一の相対的に密な層の隣の第二の相対的に密な層とのピッチは、好ましくは50~300μmであり、より好ましくは60~200μmであり、さらに好ましくは70~150μmである。
好ましくは、少なくとも5つ以上(より好ましくは少なくとも7個以上、さらに好ましくは少なくとも10個以上)の山のピークを有する。
第一の山のピークと、上記第一の山のピークの隣の第二の山のピークとのピッチは、好ましくは50~300μmであり、より好ましくは60~200μmであり、さらに好ましくは70~150μmである。
対象組織が欠損又は損傷した部位に、リン酸カルシウム成形体を適用する方法としては、切開、注射、関節鏡、内視鏡などが使用可能である。
「外部空間と連通している孔が、成形体の内部を貫通し、孔の両端において外部空間と連通している」とは、孔が、成形体のある箇所の表面から成形体の内部の空間に形成され、さらに成形体の別の箇所の表面を通じて外部空間と連通していることを示す。
第二の孔より、注入された細胞等は、第一の孔を通り成形体全体に浸潤する。
第一の孔及び第二の孔の形状は、円形、正方形、長方形、六角形、八角形、十字型、楕円のいずれでも良い。
成形体が立方体又は長方体である場合、第一の孔は、図1のように各方向に応じて、それぞれX連通孔、Y連通孔、Z連通孔を設けることができる。各連通孔は、互いに交わっても、交わらなくても良い。各連通孔の平均径は200μm~2000μmの範囲が好ましく、細胞の浸潤のし易さから200μm~1200μmがより好ましい。平均径は、例えば、キーエンス社製VHX-D510で測定することができる。径とは、孔が貫通し成形体の外表面上にあるときの孔の外周上においてある二点をとったときに、二点間の距離が最も大きくなる二点間の距離のことであり、孔の形状が円形であれば直径を意味し、四角形であれば、対角線の内の長い方を意味する。またその平均径とは、孔の数が1~4個のときには、それぞれの径の和を孔の数で割ったものを指し、5個以上のときには、4個の径の和を4で割ったものを指すものとする。
外部空間と連通している第一の孔の数は、第一の孔よりも平均径が大きい第二の孔の数よりも多いことが好ましい。
また、成形体は、例えば、移植後に体内での変形応力に耐えられるように、孔を有さない構造体の外縁部の厚さを1.3mm以上にすることが好ましい(図2の構造強化領域)。 様々な外観形状や第一の孔と第二の孔を有する複雑な成形体の形状は、コンピューター上の各種3次元CADソフト上で構築され、固有のオーダーメイド品として作成しても良いし、形と形状が定まった定型品として作成しても良い。
本発明は、表面の一部又は全部がリコンビナントゼラチンでコートされているリン酸カルシウム成形体を含む、移植用材料を提供する。
リン酸カルシウム成形体は特に限定されないが、好ましくは、本明細書中に上記した形態のリン酸カルシウム成形体を使用することができる。移植用材料に用いるリン酸カルシウムのCa/Pの原子数の比は、好ましくは1.4~1.8であり、より好ましくは1.45~1.79であり、さらに好ましくは1.50~1.70である。
リコンビナントゼラチンの詳細は本明細書中上記した通りである。リコンビナントゼラチンは、好ましくは熱架橋又は化学架橋されている。
リコンビナントゼラチンでコートされているリン酸カルシウム成形体の表面が、移植用材料の表面に存在するとは、移植用材料の表面が、リコンビナントゼラチンでコートされていることを意味する。
リコンビナントゼラチンでコートされているリン酸カルシウム成形体の表面が、移植用材料の内部に存在するとは、移植用材料、即ち、リン酸カルシウム成形体が、多孔質であり、リン酸カルシウム成形体の内部に存在する孔を形成する表面が、リコンビナントゼラチンでコートされていることを意味する。
ブロック状とは、平面のみで構成された立体形状に限らず、曲面を有する曲面立体を含む。ブロック状の一例としては、縦2.0~100.0mm、横2.0~100.0mm、及び高さ 2.0~100.0mmを有する直方体形状を挙げることができる。
顆粒状とは、粒径が約0.5~2.0mm程度の粒子の集まりを言う。
以下の実施例により本発明をさらに具体的に説明するが、本発明は実施例によって限定されるものではない。
(1)リン酸カルシウム粉末の作製方法
リン酸カルシウム粉末の原料として、Ca4(PO4)2O(リン酸四カルシウム:TTCP)と、CaHPO4・2H2O(リン酸水素カルシウム二水和物:DCPD)とを用いた。TTCPのCa/Pの原子数の比は2.0であり、DCPDのCa/Pの原子数の比は1.0である。TTCPとDCPDとの混合比率を変化させることにより、全体のCa/Pの原子数の比が異なる混合粉末を作製した。TTCPとDCPDの混合比率(モル比)とその際の混合粉末のCa/Pの原子数の比を表1に示す。
有機酸及び有機酸のナトリウム塩の混合比を調整することにより、含まれる有機酸イオンの量を一定にしながらpHの異なる溶液を作製した。具体的には、例えばクエン酸の場合、1mol/Lのクエン酸溶液と1mol/Lのクエン酸三ナトリウム溶液を混合することにより、所望のpHの溶液を作製した。
上記(1)で作製したリン酸カルシウム粉末に対して、上記(2)で作製した有機酸溶液を吐出により滴下させた。粉末および有機酸溶液を、Z-Printer310 Plus(3D Systems Corporation(旧 Z Corporation))に導入し、20×20×5mmの直方体に、2×2mmの穴が薄手方向に5カ所あいたサンプルを作製した。粉末単位体積に供給される有機酸溶液体積の比率は42%とし、リン酸カルシウム粉末の積層ピッチは100μmとした。Z-Printer310 Plusによる成形体の作製においては、リン酸カルシウム粉末を含有する層を基板上に形成する工程と、有機酸溶液をノズル部から液滴状態で吐出させて、リン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程とを反復することにより、上記の成形体が作製される。
評価B:有機酸溶液を滴下したリン酸カルシウム粉末について一部破損があった場合
評価C:有機酸溶液を滴下したリン酸カルシウム粉末が崩壊した場合
Ca/Pの原子数の比を変化させたリン酸カルシウム粉末に、pHが異なるクエン酸溶液を滴下させた場合の評価の結果を表2に示す。
2mm角の穴を有する3D(三次元)造型物データを実際に造形して、造型物の穴の大きさを測定した。実測値は常に設計値より小さく、有機酸溶液がにじむことにより、設計時に想定していない部分まで硬化してしまうと考えられる。またにじみは硬化速度が速いほど小さくなると考えられる。そこで、(実測値)/(設計値)×100を指標とし、75%以上をA、50%以上75%未満をB、25%以上50%未満をC、測定不能な場合をDとする評価を行った。この指標は100%に近いほど、設計値を再現できることを意味する。
インクとして、クエン酸1.0mol/L:クエン酸三ナトリウム二水和物1.0mol/L=3:1、の体積比で混合し、pH3.15に調整したクエン酸ナトリウム水溶液を調製した。この調製したクエン酸ナトリウム水溶液をクエン酸Naインクと称する。
混合したリン酸カルシウム粉体は、d50=17.0μmであり、粒子径5~15μmの粒子を体積基準で約35%含み、粒子径25~100μmの粒子を32%含む。レーザー回折式粒度分布測定の装置として、株式会社セイシン企業製のLMS-2000eにて、分散媒はエタノールで測定した。
成形体全域への浸透性を評価する為、PBS+(本件では、SIGMA-ALDORICH社製、D8662を使用した。PBSとは、リン酸緩衝生理食塩水のことであり、生化学等の実験で使用される緩衝液である。生体内に普遍的にあるイオンで構成されていて、組成としてはpH7.4で、NaCl、KCl、Na2HPO4、KH2PO4などが入っている。PBS+は、PBSにカルシウムとマグネシウムも入ったものである)に1.0質量%染料インク(パイロットコーポレーション製、万年筆用のBlue_Black、INK-30-BB)を加えた混合液10mLを用いて、孔のない成形体、第二の孔だけをもった成形体、第一の孔と第二の孔をもった成形体の浸透性を調べた。
実施例1の(1)で作製したCa/Pの原子数の比が1.67であるリン酸カルシウム粉末を、Z-Printer310 Plus(3D Systems Corporation(旧 Z Corporation))に導入し、pH3のクエン酸溶液を用いて、5×5×12mmの成形体を作製した。粉末単位体積に供給される有機酸溶液体積の比率は42%とし、リン酸カルシウム粉末の積層ピッチは100μmとした。Z-Printer310 Plusによる成形体の作製においては、リン酸カルシウム粉末を含有する層を基板上に形成する工程と、クエン酸溶液をノズル部から液滴状態で吐出させて、リン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程とを反復することにより、5×5×12mmの成形体が作製される。
溶液A:0.5mol/Lリン酸二水素ナトリウム溶液(pH4.3)
溶液B:0.5mol/Lリン酸水素二ナトリウム溶液(pH9)
溶液C:溶液Aと溶液Bの1:1混合溶液(pH6.6)
実施例2と同様にして作製したリン酸カルシウム成形体を、マッフル炉を用いて1100℃又は1200℃で4時間加熱した。加熱前後における圧縮強度を実施例2と同様に測定した。加熱前は2.2MPaであった圧縮強度が、1100℃での加熱の場合には3.5MPa、1200℃での加熱の場合には6.1MPaとなった。成形体の加熱により、強度が大きくなることが確認された。また、造形に用いた有機酸も熱分解により除去することができる。
(操作1)β-TCP粒子として骨補填材オスフェリオン(オリンパステルモバイオマテリアル株式会社製)を37℃にて、7.5%(配列番号1のアミノ酸配列からなるRCP)溶液に3時間、振とうしながら浸漬させた。その後、50℃にて12時間、乾燥させた。更に160℃にて20時間の熱架橋処理を施して製剤を得た。
(操作2)作製した製剤を10mg/wellとなるように 24well超低接着プレート(コーニング社製)に入れ、細胞(NIH-3T3)を50000cells/wellとなるように播種した。
(操作3)播種後、24時間で、カルセイン染色後、蛍光観察及び走査型電子顕微鏡(Scanning Electron Microscope;SEM)で観察を行った。
実施例4において、操作1を施さない以外は、実施例4と同様の操作を施した例を比較例4とした。
実験動物として、SDラット(雄、10-12週齢、0.3-0.5kg)を用い、ラットの頭頂骨を露出し、直径5 mmの円形の骨欠損部を作製した。実施例4の製剤、約10mgを作製した骨欠損部へ充填した後、皮膚を縫合した。
埋植後8週目に放血致死させて頭部を摘出した。埋入部を含む頭頂骨をHE染色にて組織学的観察をおこなった。
実施例5において、実施例4の製剤の代わりに比較例4の製剤を用いる以外は、同様の操作を施した例を比較例5とした。
リン酸カルシウム成形体を以下の通り作製した。
<リン酸カルシウム成形体の製造方法>
インクとして、クエン酸1.2mol/L:クエン酸三ナトリウム二水和物1.2mol/L=3:1、の体積比で混合し、pH3.15に調整したクエン酸ナトリウム水溶液を調製した。 この調製したクエン酸ナトリウム水溶液をクエン酸Naインクと称する。
混合したリン酸Ca粉体は、粒子径5~15μmの粒子を体積基準で約35%含み、粒子径25~100μmの粒子を32%含む。 レーザー回折式粒度分布測定の装置として、株式会社セイシン企業製のLMS-2000eにて、分散媒はエタノールで測定した。
・構造物は円柱状であり、焼結すると10%縮むことを考えて、直径Φ8.8mm、高さ22mmで造形した。
スーパーポア(ペンタックス社製)品番KB-6-1、径8×長さ20mm
スーパーポア(ペンタックス社製)品番HB-50-0820、径8×長さ20mm
スーパーポアEX(ペンタックス社製)品番XC-0820、径8×L20mm
上記3種のスーパーポアは、β型リン酸三カルシウムからなる白色多孔体である。
気孔率は、水銀圧入法で測定した。水銀圧入法とは、水銀の表面張力が大きいことを利用して粉体の細孔に水銀を浸入させるために圧力を加え、圧力と圧入された水銀量から比表面積や細孔分布を求める方法である。POREMASTER 60GT(Quantachrome社製)を使用して測定した。以下の標準的な条件で測定した。
Hg Surface Tension 480.00erg/cm2
Hg Contact Angle (I)141.30°,(E)141.30°
温度20.00[℃]
サンプルサイズは、径0.462mm、高さ0.959mmの円柱状である。
上記で作製したリン酸カルシウム成形体の重量を1/1000gまで測定可能な電子天秤で測定し、直径と高さを1/100mmまで測定可能なノギスで、測定して体積を求めた。 次に、重量を体積で割って、比重を求めた。
吸水浸透速度を求める実験系を構築した。
実験室の温度を23℃、湿度を30%とし実験測定した。 万年筆インクとして、パイロットコーポレーション製のINK-30-BBを使用した。
内径2mmのプラスチック筒とチューブとシリンジにより、図7に示す実験系を構築した。構造物の底面にメニスカス面を作ってそこから浸透させた。メニスカス高さは、目視、手動で調整した。リン酸カルシウム成形体21は、径8mm×20mm高さとした。プラスチック筒22の内径は2mmである。チューブ23の長さは100mmである。水位24については、プラスチック筒22とリン酸カルシウム成形体21の接する高さに、吸水浸透の開始から終了まで調整した。シリンジ25は、10mLのシリンジを使用した。リン酸カルシウム成形体21より内径を大きくした。
<リン酸カルシウム成形体の製造方法>
インクとして、クエン酸1.2mol/L:クエン酸三ナトリウム二水和物1.2mol/L=3:1、の体積比で混合し、pH3.15に調整したクエン酸ナトリウム水溶液を調製した。 この調製したクエン酸ナトリウム水溶液をクエン酸Naインクと称する。
粉体として、メジアン径(以下d50と表記)7.4μmのTTCP、d50=19.5μmのDCPD粉体を用意し、最終的にCa/Pの原子数の比が1.5になるように混合した。
より具体的には、モル比でTTCP:DCPD=1:2、TTCP:DCPD=219.8g:206.5gで混合した。この混合物をリン酸Ca粉体とする。混合したリン酸Ca粉体は、粒子径5~15μmの粒子を体積基準で約35%含み、粒子径25~100μmの粒子を32%含む。
3Dプリンター(Zprinter310plus)を用い、インクと粉体をクエン酸Naインク、リン酸Ca粉体に置き換え、積層厚みを100μmとした。
構造物は円盤を3個重ねた構造であり、一番大きな円盤は直径14.4mmで、全高7.8mmの円盤状である。
3Dプリンターで成形した後、35℃の3Dプリンター内で1時間、乾燥させ、余剰な粉体を圧空(エアーガンから0.15MPaに調整した圧縮空気をだすエアーブロー流)で除去した。この成形体をマッフル炉にて、1時間につき100℃ずつ昇温させた後、1100℃で2時間焼結し、焼結の為の加熱をoffにし、マッフル炉の蓋は開けない状態で、8時間以上静置する。マッフル炉が100℃以下の温度になった後、焼結の済んだ成形体を取り出し、成形体を得た。
疎密積層構造の解析に用いた対象物の構造を図8に示す。
ゼネラルエレクトロ二クス社製のphoenix nanotom mにより以下の測定条件において観察及び解析を行った。
管電圧: 120kV
管電流: 90μA
X線源から検出器までの距離 (FDD): 600 mm
X線源から対象サンプルの回転中心までの距離 (FOD): 400 mm
解像度: X軸、Y軸、Z軸ともに6.66μm
図9のように、リン酸カルシウム成形体の向きを調整し、白と黒のストライプ模様に対し、直交する方向をリン酸カルシウム成形体のZ軸とする。
2.0mm以上のより広い領域を選択するのが、リン酸カルシウム成形体の局所性に影響されずに済むので好ましいが、リン酸カルシウム成形体が小さい場合は実施できないので適宜調整する。 大きすぎると後の作業が大変になるので、5.0mmを上限とし、4.0mmまでがより好ましい。
2.0mm以上のより広い領域を選択するのがリン酸カルシウム成形体の局所性からの影響とピクセルの分解能に影響されずに済むので好ましいが、リン酸カルシウム成形体が小さい場合は実施できないので適宜調整する。大きすぎると、リン酸カルシウム成形体の疎層と密層の向きとVGStudio Max 3.0.3 64bit内で構築するX軸、Y軸、Z軸向きの一致性の影響がでるので、5.0mmを上限とし、4.0mmまでとするのがより好ましい。
密層の頂点の数を数える。 密層の頂点とは、相対的にその周辺より物質密度が高くなる、波形の傾きの係数がプラスからマイナスに転じるところである。 疎層の頂点とは、相対的にその周辺より物質密度が小さくなるところであり、波形の傾きの係数がマイナスからプラスに転じるところである。
(密層の頂点の数/Z軸の距離)= リン酸カルシウム成形体の疎密積層構造のZX平面のピッチとする。本件は3.0mm/34個で88.2μmがピッチとなる(図11)。
(密層の頂点の数/Z軸の距離)= リン酸カルシウム成形体の疎密積層構造のYZ平面のピッチとする。 本件は3.0mm/32個で93.8μmがピッチとなる(図13)
リン酸カルシウム粉末として、Ca4(PO4)2O(リン酸四カルシウム:TTCP)、CaHPO4・2H2O(リン酸水素カルシウム二水和物:DCPD)、及びTTCPとDCPDとの混合粉体(Ca/Pの原子数の比は1.5)を用いて、以下の方法及び条件で粒度分布を測定した。
測定原理: 水やエタノールなどの分散媒に分散された粒子にレーザー光照射し、粒子からの散乱光強度の角度依存性を測定することにより、サンプルに含まれる粒子の粒子径分布を求める。
測定範囲: 0.02~2000μm
レーザー光源:ヘリウムネオンレーザー
分散媒: エタノール
測定方法: 分散媒のみでブランク測定を行ったのち、1分間の超音波分散により試料を分散させ、超音波分散した試料を分散槽に入れ循環式にて粒度分布測定を行う。
粒度分布: 体積基準で表示。
粉体として、微細側から累積10%のときの粒径(μ m)をd10、微細側から累積25%のときの粒径(μ m)をd25、微細側から累積50%のときの粒径(μ m)をd50、微細側から累積75%のときの粒径(μ m)をd75、微細側から累積90%のときの粒径(μ m)をd90と表したとき、TTCPはメジアン径にあたるd50=7.4μm、DCPDはd50=19.5μmとなる。 最終的にCa/Pの原子数の比が1.5になるように混合した、より具体的には、モル比でTTCP:DCPD=1:2、TTCP:DCPD=219.8g:206.5gで混合した、この混合物をリン酸Ca粉体とする。
混合したリン酸カルシウム粉体は、d50=17.0μmであり、粒子径5~15μmの粒子を体積基準で約35%含み、粒子径25~100μmの粒子を32%含む。
粉体として、平均粒子径7μmのTTCP、平均粒子径60μmのDCPD、並びにTTCPとDCPDの混合物(Ca/Pの原子数の比が1.5になるように混合したもの)を用意した。TTCPとDCPDの混合物としては、より具体的には、モル比でTTCP:DCPD=1:2、TTCP:DCPD=219.8g:206.5gで混合した。
上記の粉体の流動性(フローファンクション)を以下の方法で測定した。測定装置としては、ブルックフィールド製の「パウダーフローテスター、PFT」を用いて、スタンダードフローファンクションを選択して測定した、フローファンクションは、破壊強度をfc、最大主応力をσ1とした時、σ1/fcで表される値である。フローファンクション値は、以下の基準で評価した。
一般的に、流動性は粒子径と関係あって、粒子径が小さいと流動性が悪くなる。 粒子径が小さいほど、比表面積が大きくなり、質量と比例する体積よりも、表面の影響がでて、ある粉体粒子の表面と隣り合う粉体粒子の表面に働く、ファンデルワールス力、静電気力など、粒子を引き合わせる引力の影響が大きくでる。
TTCPとDCPDを所定のモル比で混合するとd50=17.0μmとなり、粒子径5~15μmの粒子を体積基準で約35%含んでいても、粒子径25~100μmの粒子を32%含む影響がでて、流動性がTTCPのみでは3.34というフローファンクション値であったのが、混合粉体では4.87と、DCPDのみでの5.13とう値に近くづく。 これによりリコート不良も発生せず、3D粉体積層プリントすることが可能になる。
CBE3(配列番号1のアミノ酸配列からなるリコンビナントゼラチン)を被覆したリン酸カルシウム成形体を用いて骨再生の評価試験を行った。
<リン酸カルシウム成形体の製造方法>
インクとして、クエン酸1.2mol/L:クエン酸三ナトリウム二水和物1.2mol/L=3:1、の体積比で混合し、pH3.15に調整したクエン酸ナトリウム水溶液を調製した。 この調製したクエン酸ナトリウム水溶液をクエン酸Naインクと称する。
混合したリン酸Ca粉体は、粒子径5~15μmの粒子を体積基準で約35%含み、粒子径25~100μmの粒子を32%含む。
・構造物は直径Φ5mm、高さ1.9mmの円盤状である。
・円盤の底面と平行に、円盤の中間くらいの高さに、X方向とY方向に、0.7×1.0mの連通孔が十字形状に形成されている。
・十字形状の中心を貫くようにZ軸方向にΦ1.1mmの連通孔が形成されている。
・円盤の上面側にも、連通孔と上側に、X方向とY方向に、幅1.8mmで高さ0.4mmの凸部が形成されている。
光製薬株式会社製の注射水溶液に7質量%のCBE3を溶解させ、45℃のオーブンで30分加熱し、溶解して、CBE3水溶液を作製した。
CBE3水溶液に、リン酸カルシウム成形体を浸漬し、デシケーター内で、大気圧から-0.09MPaまで真空脱気処理し、水溶液に溶解している空気やリン酸Ca成形体の内部にある空隙から空気を取り除きつつ、10分間放置する。大気状態に戻したあと2回同様の操作を行ったあと、取り出して、リン酸Ca成形体に付着している余剰なCBE3水溶液を取り除き、50℃のオーブンにて3時間乾燥する。
CBE3の熱架橋は以下の通り行った。真空引きと窒素置換が可能なオーブンにて、2hPa程度まで真空引きと窒素置換を数度繰り返したのち、1013hPaの窒素雰囲気下で約150℃の4時間程度に加熱する。
試験期間終了後、放血死させたラットより頭部を回収し、眼球、脳等の軟組織を除去したのち。得られた標本より埋植部をトリミングし、樹脂包埋した。同包埋標本からミクロトームにより5μm厚の切片を切出し、ヘマトキシリン&エオジン染色(H&E)とvon Kossa染色を行った。
試験A(コントロール:欠損のみ)について、マイクロフォーカスCT解析を行った。マイクロフォーカスCTは株式会社リガク製のR-mCTであり、管電圧は90kV 、管電流は100μA、X線焦点-検出器 の距離(FDD)は292 mm、X線焦点-回転中心の距離 (FOD)は73 mmである。マイクロフォーカスCTの解析結果を図18に示す。マイクロフォーカスCT解析において、コントロール(欠損のみ)は、既存骨の外周部からの骨再生は見られるが、ラット頭部の欠損を補填するような再生はみられない。
<リン酸カルシウム成形体の製造方法>
クエン酸1.0mol/L:クエン酸三ナトリウム二水和物1.0mol/L=3:1、の体積比で混合し、pH3.15に調整した1.0mol/Lのクエン酸ナトリウム水溶液を調製した。
クエン酸1.2mol/L:クエン酸三ナトリウム二水和物1.2mol/L=3:1、の体積比で混合し、pH3.15に調整した1.2mol/Lクエン酸ナトリウム水溶液を調製した。
混合したリン酸Ca粉体は、粒子径5~15μmの粒子を体積基準で約35%含み、粒子径25~100μmの粒子を32%含む。レーザー回折式粒度分布測定の装置として、株式会社セイシン企業製のLMS-2000eにて、分散媒はエタノールで測定した。
有機酸溶液の塗布量は、3Dプリンターからリン酸カルシウム粉体を除き、重量を測定したおいたプラスチック容器を、本来、リン酸カルシウム成形体が形成される場所おいて、プラスチック容器に対し、1cm3設計の立体物を造形するよる有機酸溶液を吐出し、有機酸溶液がのった状態でプラスチック容器の重量を測定し、吐出された有機酸溶液の重量を測定する。 1cm3設計の立体物を造形するのに要した有機酸溶液の重量を有機酸溶液の塗布量として、g/1cm3という単位であらわす。
圧縮強度の測定は、株式会社イマダ製の縦型電動計測スタンドMX2と同じく株式会社イマダ製のデジタルフォースゲージZTA-1000Nを用いて行った。約18×18×7.2mmサンプルの長手方向に,0.17mm/秒の速度で荷重をかけ、サンプルの形状は正確にノギスにより測定し、サンプル破壊時の最大荷重(N)を断面積で割ることにより圧縮強度(MPa)を求めた。
底面の反りの評価は、以下の基準で行った。クラス1から5の見本を図26に示す。
12 第一の孔のY連通孔
13 第一の孔のZ連通孔
14 第一の孔のXYZ連通孔
15,06 縫合孔
16,02 第二の孔
17 構造強化領域
04 第一の孔
21 リン酸カルシウム成形体
22 プラスチック筒
23 チューブ
24 水位
25 シリンジ
Claims (38)
- Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を含有する層を基板上に形成する工程a;及び
有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液をノズル部から液滴状態で吐出させて、前記有機酸溶液を前記工程aで形成したリン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程b;
を含む、リン酸カルシウム成形体の製造方法。 - 前記工程bで使用する有機酸が、クエン酸、シュウ酸、酒石酸、マロン酸及びリンゴ酸からなる群から選択される少なくとも1種である、請求項1に記載のリン酸カルシウム成形体の製造方法。
- 前記工程bの後に、
Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウム粉末を含有する層を、前記工程aで形成したリン酸カルシウム粉末を含有する層の上に形成する工程c;及び
有機酸のカルシウム塩の水に対する溶解度が1g/100mL以下であり、かつpH3.5以下である有機酸溶液をノズル部から液滴状態で吐出させて、前記有機酸溶液を前記工程cで形成したリン酸カルシウム粉末を含有する層に対して滴下させることによりリン酸カルシウム成形体を製造する工程d;
をさらに含む、請求項1又は2に記載のリン酸カルシウム成形体の製造方法。 - 前記工程dで使用する有機酸が、クエン酸、シュウ酸、酒石酸、マロン酸及びリンゴ酸からなる群から選択される少なくとも1種である、請求項3に記載のリン酸カルシウム成形体の製造方法。
- 前記リン酸カルシウム粉末は、第一のリン酸カルシウム粉末と第二のリン酸カルシウム粉末とを含み、第一のリン酸カルシウム粉末の前記有機酸に対する溶解性が、第二のリン酸カルシウム粉末の前記有機酸に対する溶解性よりも高く、
第一のリン酸カルシウム粉末と第二のリン酸カルシウム粉末とを含む前記リン酸カルシウム粉末は、粒子径5~15μmの粒子と、粒子径25~100μmの粒子とを少なくとも含み、粒子径25μm以上の粒子を体積基準で20%以上含む、請求項1から4の何れか一項に記載のリン酸カルシウム成形体の製造方法。 - 第一のリン酸カルシウム粉末のフローファンクションが4.00未満であり、
第一のリン酸カルシウム粉末と第二のリン酸カルシウム粉末とを含む前記リン酸カルシウム粉末のフローファンクションが4.00以上である、請求項5に記載のリン酸カルシウム成形体の製造方法:但し、フローファンクションは、破壊強度をfc、最大主応力をσ1とした時、σ1/fcで表される。 - 工程bおよび/又は工程dにおける有機酸溶液の濃度が1.1mol/L以上1.4mol/L以下である、請求項1から6の何れか一項に記載のリン酸カルシウム成形体の製造方法。
- 工程bおよび/又は工程dにおける有機酸が、クエン酸である、請求項7に記載のリン酸カルシウム成形体の製造方法。
- 工程bおよび/又は工程dにおける有機酸溶液の塗布量が、0.20g/cm3以上0.30g/cm3以下である、請求項7又は8に記載のリン酸カルシウム成形体の製造方法。
- 工程bおよび/又は工程dにおける有機酸溶液のpHが、2.5以上3.5以下である、請求項1から9の何れか一項に記載のリン酸カルシウム成形体の製造方法。
- 成形体の形成に使用されなかった、リン酸カルシウム粉末を除去する工程eをさらに含む、請求項1から10のいずれか一項に記載のリン酸カルシウム成形体の製造方法。
- 前記工程eの後、成形体を水溶液に浸漬することにより成形体を硬化させる工程f、及び/又は成形体を加熱することにより成形体を硬化させる工程gを含む、請求項11に記載のリン酸カルシウム成形体の製造方法。
- 成形体に生体親和性高分子を被覆する工程hをさらに含む、請求項1から12のいずれか一項に記載のリン酸カルシウム成形体の製造方法。
- 前記生体親和性高分子が、リコンビナントゼラチンである、請求項13に記載のリン酸カルシウム成形体の製造方法。
- 前記工程hの後に、前記生体親和性高分子に細胞を播種する工程iをさらに含む、請求項13又は14に記載のリン酸カルシウム成形体の製造方法。
- リン酸カルシウム成形体が、再生医療用足場材又は組織修復材である、請求項1から15のいずれか一項に記載のリン酸カルシウム成形体の製造方法。
- 請求項1から16のいずれか一項に記載のリン酸カルシウム成形体の製造方法により製造されるリン酸カルシウム成形体。
- 再生医療用足場材又は組織修復材である、請求項17に記載のリン酸カルシウム成形体。
- 外部空間と連通している孔を有している、請求項17又は18に記載のリン酸カルシウム成形体。
- 外部空間と連通している孔が、成形体の内部を貫通し、孔の両端において外部空間と連通している、請求項19に記載のリン酸カルシウム成形体。
- 外部空間と連通している孔の平均径が200μm~2000μmである、請求項19又は20に記載のリン酸カルシウム成形体。
- Ca/Pの原子数の比が1.4~1.8であるリン酸カルシウムから形成されるリン酸カルシウム成形体であって、
外部空間と連通している第一の孔及び当該第一の孔よりも平均径が大きい第二の孔を有する、リン酸カルシウム成形体。 - 外部空間と連通している第一の孔の平均径が200μm~2000μmである、請求項22に記載のリン酸カルシウム成形体。
- 外部空間と連通している第一の孔の数が、第一の孔よりも平均径が大きい第二の孔の数よりも多い、請求項22又は23に記載のリン酸カルシウム成形体。
- 表面の一部又は全部がリコンビナントゼラチンでコートされているリン酸カルシウム成形体を含む、移植用材料。
- 前記リン酸カルシウムのCa/Pの原子数の比が1.4~1.8である、請求項25に記載の移植用材料。
- リコンビナントペプチドが、熱架橋又は化学架橋されている、請求項25又は26に記載の移植用材料。
- リコンビナントペプチドでコートされているリン酸カルシウム成形体の表面が、移植用材料の表面および内部に存在する、請求項25から27の何れか一項に記載の移植用材料。
- リン酸カルシウム成形体が、ブロック状である、請求項25から28の何れか一項に記載の移植用材料。
- リン酸カルシウム成形体が、顆粒状である、請求項25から28の何れか一項に記載の移植用材料。
- リン酸カルシウムから形成されるリン酸カルシウム成形体であって、
外部空間と連通している孔を有し、
比重が0.7g/mL以上であるか、および/又は水銀注入法による気孔率が75%以下であり、
吸水浸透速度が、0.05mm/秒以上である、
リン酸カルシウム成形体;
但し、吸水浸透速度とは、以下の条件で測定したものである。直径8mm高さ20mmのリン酸カルシウム成形体に、内径2mmのプラスチック筒の一端を連結し、前記プラスチック筒の他端を長さ100mmのチューブの一端に連結し、前記チューブの他端を10mLのシリンジに連結した実験系を構築する。リン酸カルシウム成形体とプラスチック筒の接する高さと、シリンジ内のインキの水位の高さとが吸水浸透の開始から終了まで同じになるように調整した条件下において、シリンジ内のインキをリン酸カルシウム成形体に吸水浸透させる。インキが浸透したリン酸カルシウム成形体の領域の高さが5分以内に15mmとなったときは、15mmを浸透に要した時間で割った値を吸水浸透速度とし、インキが浸透したリン酸カルシウム成形体の領域の高さが5分以内に15mmとならない場合は、5分の時点においてインキが浸透したリン酸カルシウム成形体の領域の高さを、浸透に要した時間である5分で割った値を、吸水浸透速度とする。 - 前記リン酸カルシウムのCa/Pの原子数の比が1.4~1.8である、請求項31に記載のリン酸カルシウム成形体。
- ナノフォーカスX線CT又はマイクロフォーカスX線CTによる測定により判別される相対的に密な層と相対的に疎な層とが交互に積層された構造を有している、請求項31又は32に記載のリン酸カルシウム成形体。
- 少なくとも5層以上の相対的に密な層と、少なくとも5層以上の相対的に疎な層とが交互に積層されている、請求項33に記載のリン酸カルシウム成形体。
- 第一の相対的に密な層と、前記第一の相対的に密な層の隣の第二の相対的に密な層とのピッチが50~300μmである、請求項33又は34に記載のリン酸カルシウム成形体。
- リン酸カルシウム成形体のナノフォーカスX線CT画像に基づいて、成形体の一方向の距離を横軸に、相対CT強度を縦軸に表示した波形図において、山のピークと谷のピークとを交互に有する、請求項31又は32に記載のリン酸カルシウム成形体。
- 少なくとも5つ以上の山のピークを有する、請求項36に記載のリン酸カルシウム成形体。
- 第一の山のピークと、前記第一の山のピークの隣の第二の山のピークとのピッチが50~300μmである、請求項36又は37に記載のリン酸カルシウム成形体。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17806689.0A EP3466905B1 (en) | 2016-05-30 | 2017-05-30 | Method for producing calcium phosphate molded article, calcium phosphate molded article, and material for transplantation |
JP2018520931A JP6728350B2 (ja) | 2016-05-30 | 2017-05-30 | リン酸カルシウム成形体の製造方法、リン酸カルシウム成形体及び移植用材料 |
KR1020187034917A KR102204763B1 (ko) | 2016-05-30 | 2017-05-30 | 인산 칼슘 성형체의 제조 방법, 인산 칼슘 성형체 및 이식용 재료 |
CN201780033977.5A CN109219587B (zh) | 2016-05-30 | 2017-05-30 | 磷酸钙成型体的制造方法、磷酸钙成型体及移植用材料 |
EP21206895.1A EP3974403A1 (en) | 2016-05-30 | 2017-05-30 | Method for producing calcium phosphate molded article, calcium phosphate molded article, and material for transplantation |
US16/204,987 US10953131B2 (en) | 2016-05-30 | 2018-11-29 | Method for producing calcium phosphate molded article, calcium phosphate molded article, and material for transplantation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016107615 | 2016-05-30 | ||
JP2016-107615 | 2016-05-30 | ||
JP2016-239826 | 2016-12-09 | ||
JP2016239826 | 2016-12-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/204,987 Continuation US10953131B2 (en) | 2016-05-30 | 2018-11-29 | Method for producing calcium phosphate molded article, calcium phosphate molded article, and material for transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017209136A1 true WO2017209136A1 (ja) | 2017-12-07 |
Family
ID=60477585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/020130 WO2017209136A1 (ja) | 2016-05-30 | 2017-05-30 | リン酸カルシウム成形体の製造方法、リン酸カルシウム成形体及び移植用材料 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10953131B2 (ja) |
EP (2) | EP3466905B1 (ja) |
JP (2) | JP6728350B2 (ja) |
KR (1) | KR102204763B1 (ja) |
CN (1) | CN109219587B (ja) |
WO (1) | WO2017209136A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023504036A (ja) * | 2019-11-26 | 2023-02-01 | ティーアンドアール バイオファブ カンパニー リミテッド | バイオインク供給システム及びそれを用いた3dバイオプリンティング方法 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1014176A2 (en) | 1998-12-23 | 2000-06-28 | Fuji Photo Film B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
JP2001095913A (ja) | 1999-09-28 | 2001-04-10 | Asahi Optical Co Ltd | リン酸カルシウムセメントおよびリン酸カルシウム粉体 |
JP2004202126A (ja) * | 2002-12-26 | 2004-07-22 | Next:Kk | 人工骨成形方法 |
WO2004085473A2 (en) | 2003-03-28 | 2004-10-07 | Fuji Photo Film B.V. | Rgd-enriched gelatine-like proteins with enhanced cell binding |
WO2005011536A1 (ja) | 2003-07-31 | 2005-02-10 | Riken | 粉末積層法による人工骨成形方法 |
WO2005105164A1 (ja) * | 2004-04-30 | 2005-11-10 | Sunstar Suisse Sa | 生体適合膜及びその製造方法 |
US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
JP2006025915A (ja) | 2004-07-13 | 2006-02-02 | Pentax Corp | リン酸カルシウム系骨補填材の製造方法 |
WO2008103041A1 (en) | 2007-02-21 | 2008-08-28 | Fujifilm Manufacturing Europe B.V. | Recombinant gelatins |
JP2012004555A (ja) | 2010-05-20 | 2012-01-05 | Fujifilm Corp | 傾斜機能材料の製造方法及び装置 |
JP2013106721A (ja) | 2011-11-18 | 2013-06-06 | Fujifilm Corp | 組織再生用部材、その形成方法、及びインク |
JP2013202213A (ja) * | 2012-03-28 | 2013-10-07 | Fujifilm Corp | 硬組織再生用材料 |
JP2015174792A (ja) * | 2014-03-14 | 2015-10-05 | 株式会社リコー | 積層造形用粉末材料及び積層造形物の製造方法 |
JP2015187058A (ja) | 2014-03-14 | 2015-10-29 | 株式会社リコー | 積層造形用粉末材料、積層造形セット、及び積層造形物の製造方法 |
WO2015194678A1 (ja) * | 2014-06-20 | 2015-12-23 | 株式会社フジミインコーポレーテッド | 粉末積層造形に用いる粉末材料およびそれを用いた粉末積層造形法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5645814A (en) * | 1979-09-25 | 1981-04-25 | Kureha Chem Ind Co Ltd | Hydroxyapatite, its ceramic material and its manufacture |
CA2442855A1 (en) * | 2001-04-12 | 2002-10-24 | Therics, Inc. | Method and apparatus for engineered regenerative biostructures |
JP4214051B2 (ja) * | 2001-05-30 | 2009-01-28 | 啓一 宮本 | エラスチン架橋体およびその製造方法 |
CN1460526A (zh) * | 2003-06-13 | 2003-12-10 | 四川大学 | 含有羟基磷灰石成分的多孔型骨修复体及其制备方法 |
KR100583849B1 (ko) | 2004-01-20 | 2006-05-26 | 재단법인서울대학교산학협력재단 | 인산칼슘 화합물의 폴리메릭 졸 제조방법 |
EP1945144A4 (en) * | 2005-10-19 | 2012-12-05 | Kenton W Gregory | PROCESS FOR THE USE AND PRODUCTION OF TROPOELASTIN AND BIOMATERIALS BASED ON TROPOELASTIN |
US8147860B2 (en) * | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
DE102006062000A1 (de) | 2006-12-29 | 2008-07-03 | Robert Bosch Gmbh | Stationäre, motorbetriebene Unterflursäge |
WO2010004057A1 (es) | 2008-07-08 | 2010-01-14 | Histocell, S.L | MATRICES TRIDIMENSIONALES DE MONETITA POROSA ESTRUCTURADA PARA INGENIERIA TISULAR Y REGENERACION OSEA, Y METODO DE PREPARACIόN DE LAS MISMAS |
EP2478923B1 (en) * | 2009-09-04 | 2016-05-04 | FUJIFILM Corporation | A bone regeneration agent comprising gelatin |
CN101745148B (zh) * | 2009-12-31 | 2013-04-10 | 四川大学 | 一种等离子喷涂三维多孔钛生物活性涂层的制备方法 |
US20120210909A1 (en) * | 2011-02-21 | 2012-08-23 | Tien-Min Gabriel Chu | Calcim phosphate cement reinforcement by polymer infiltration and in situ curing |
US9004906B2 (en) * | 2011-02-28 | 2015-04-14 | Mold-Masters (2007) Limited | Cavity insert film flow cooling |
US20160008507A1 (en) * | 2013-03-13 | 2016-01-14 | National Institute For Materials Science | Adhesive bone filling agent and adhesive bone filling agent kit |
US9487443B2 (en) * | 2014-03-14 | 2016-11-08 | Ricoh Company, Ltd. | Layer stack formation powder material, powder layer stack formation hardening liquid, layer stack formation material set, and layer stack object formation method |
JP6524828B2 (ja) | 2015-07-09 | 2019-06-05 | 王子ホールディングス株式会社 | 滅菌紙および滅菌包装体 |
-
2017
- 2017-05-30 EP EP17806689.0A patent/EP3466905B1/en active Active
- 2017-05-30 WO PCT/JP2017/020130 patent/WO2017209136A1/ja unknown
- 2017-05-30 EP EP21206895.1A patent/EP3974403A1/en not_active Withdrawn
- 2017-05-30 CN CN201780033977.5A patent/CN109219587B/zh active Active
- 2017-05-30 JP JP2018520931A patent/JP6728350B2/ja active Active
- 2017-05-30 KR KR1020187034917A patent/KR102204763B1/ko active IP Right Grant
-
2018
- 2018-11-29 US US16/204,987 patent/US10953131B2/en active Active
-
2020
- 2020-07-01 JP JP2020113988A patent/JP2020168426A/ja not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1014176B1 (en) | 1998-12-23 | 2009-04-29 | FUJIFILM Manufacturing Europe B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
EP1014176A2 (en) | 1998-12-23 | 2000-06-28 | Fuji Photo Film B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
JP2001095913A (ja) | 1999-09-28 | 2001-04-10 | Asahi Optical Co Ltd | リン酸カルシウムセメントおよびリン酸カルシウム粉体 |
US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
JP2004202126A (ja) * | 2002-12-26 | 2004-07-22 | Next:Kk | 人工骨成形方法 |
WO2004085473A2 (en) | 2003-03-28 | 2004-10-07 | Fuji Photo Film B.V. | Rgd-enriched gelatine-like proteins with enhanced cell binding |
WO2005011536A1 (ja) | 2003-07-31 | 2005-02-10 | Riken | 粉末積層法による人工骨成形方法 |
WO2005105164A1 (ja) * | 2004-04-30 | 2005-11-10 | Sunstar Suisse Sa | 生体適合膜及びその製造方法 |
JP2006025915A (ja) | 2004-07-13 | 2006-02-02 | Pentax Corp | リン酸カルシウム系骨補填材の製造方法 |
WO2008103041A1 (en) | 2007-02-21 | 2008-08-28 | Fujifilm Manufacturing Europe B.V. | Recombinant gelatins |
JP2012004555A (ja) | 2010-05-20 | 2012-01-05 | Fujifilm Corp | 傾斜機能材料の製造方法及び装置 |
JP2013106721A (ja) | 2011-11-18 | 2013-06-06 | Fujifilm Corp | 組織再生用部材、その形成方法、及びインク |
JP2013202213A (ja) * | 2012-03-28 | 2013-10-07 | Fujifilm Corp | 硬組織再生用材料 |
JP2015174792A (ja) * | 2014-03-14 | 2015-10-05 | 株式会社リコー | 積層造形用粉末材料及び積層造形物の製造方法 |
JP2015187058A (ja) | 2014-03-14 | 2015-10-29 | 株式会社リコー | 積層造形用粉末材料、積層造形セット、及び積層造形物の製造方法 |
WO2015194678A1 (ja) * | 2014-06-20 | 2015-12-23 | 株式会社フジミインコーポレーテッド | 粉末積層造形に用いる粉末材料およびそれを用いた粉末積層造形法 |
Non-Patent Citations (11)
Title |
---|
"asic Local Alignment Search Tool)) program", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
"Byotai Seiri (Pathologic physiology", vol. 9, 1990, NAGAI SHUPPAN K.K., pages: 527 |
FRAGRANCE JOURNAL, vol. 50, 1981, pages 79 - 82 |
GASTEIGER E.; GATTIKER A.; HOOGLAND C.; IVANYI I.; APPEL R.D.; BAIROCH A.: "ExPASy: the proteomics server for in-depth protein knowledge and analysis.", NUCLEIC ACIDS RES., vol. 31, 2003, pages 3784 - 3788 |
GASTEIGER E.; HOOGLAND C.; GATTIKER A.; DUVAUD S.; WILKINS M.R.; APPEL R.D.; BAIROCH A.: "The Proteomics Protocols Handbook", 2005, HUMANA PRESS, article "Protein Identification and Analysis Tools on the ExPASy Server", pages: 571 - 607 |
KAGAKU NO RYOIKI (REALM OF CHEMISTRY, vol. 11, no. 10, 1957, pages 719 - 725 |
KODANSHA LTD.: "Dictionary of Inorganic Compounds & Complexes", 10 June 1997, article MASAYOSHI NAKAHARA, pages: 163, XP009512154 * |
MAXEY, C.R.: "Phitogr. Gelatin", vol. 2, 1976, article "Isoelectric Point Electrophoresis Method" |
PHARMACEUTICAL BULLETIN, vol. 2, no. 2, 1954, pages 163 - 173 |
See also references of EP3466905A4 |
YOSHIO KODA ET AL.: "Shinpan Yuki Gainenzu - Kiso to Oyo (New Edition of Organic Conceptual Diagram - Fundamentals and Applications", 2008, SANKYO SHUPPAN CO., LTD. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023504036A (ja) * | 2019-11-26 | 2023-02-01 | ティーアンドアール バイオファブ カンパニー リミテッド | バイオインク供給システム及びそれを用いた3dバイオプリンティング方法 |
JP7352994B2 (ja) | 2019-11-26 | 2023-09-29 | ティーアンドアール バイオファブ カンパニー リミテッド | バイオインク供給システム及びそれを用いた3dバイオプリンティング方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109219587A (zh) | 2019-01-15 |
JPWO2017209136A1 (ja) | 2019-05-16 |
EP3466905B1 (en) | 2021-12-15 |
JP2020168426A (ja) | 2020-10-15 |
CN109219587B (zh) | 2021-09-14 |
JP6728350B2 (ja) | 2020-07-22 |
KR102204763B1 (ko) | 2021-01-19 |
KR20190004760A (ko) | 2019-01-14 |
EP3974403A1 (en) | 2022-03-30 |
US20190167841A1 (en) | 2019-06-06 |
US10953131B2 (en) | 2021-03-23 |
EP3466905A4 (en) | 2019-10-16 |
EP3466905A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ratheesh et al. | 3D fabrication of polymeric scaffolds for regenerative therapy | |
US20230248885A1 (en) | Ceramic-containing bioactive inks and printing methods for tissue engineering applications | |
JP5889780B2 (ja) | 細胞支持体及び骨再生材 | |
Wang et al. | Tissue-specific engineering: 3D bioprinting in regenerative medicine | |
Kumar et al. | Biological functionality of extracellular matrix‐ornamented three‐dimensional printed hydroxyapatite scaffolds | |
Liu et al. | Electrospinning and 3D printed hybrid bi-layer scaffold for guided bone regeneration | |
WO2010001578A1 (ja) | 骨成長因子を吸着し,その活性を阻害しない骨補填剤 | |
EP3358003B1 (en) | Method for producing sheet-like cell structure and sheet-like cell structure | |
Kim et al. | BMP-2-immobilized porous matrix with leaf-stacked structure as a bioactive GBR membrane | |
Song et al. | Three dimensional plotted extracellular matrix scaffolds using a rapid prototyping for tissue engineering application | |
Ahadian et al. | Biomaterials in tissue engineering | |
Balla et al. | Biointegration of three-dimensional–printed biomaterials and biomedical devices | |
Parupelli et al. | 3D printing of PCL-ceramic composite scaffolds for bone tissue engineering applications | |
JP4893915B2 (ja) | 移植材料 | |
JP6728350B2 (ja) | リン酸カルシウム成形体の製造方法、リン酸カルシウム成形体及び移植用材料 | |
Sun et al. | Scaffold with orientated microtubule structure containing polylysine-heparin sodium nanoparticles for the controlled release of TGF-β1 in cartilage tissue engineering | |
JPWO2020050205A1 (ja) | ゲル形成キット、ゲルおよびゲルの製造方法 | |
He et al. | Recent Advancements of Bioinks for 3D Bioprinting of Human Tissues and Organs | |
Gao et al. | Evaluation of the osteogenesis of 3D printing poly (lactic-co-glycolic acid)-hydroxyapatite scaffolds in a rat femur model and its biocompatibility | |
Gupta et al. | Is it possible to 3D bioprint load-bearing bone implants? A critical | |
Ji | Development of Novel Inks and Approaches for Printing Tissues and Organs | |
Andreani et al. | Cell scaffolds and fabrication technologies for tissue engineering | |
KR20230078572A (ko) | 아텔로콜라겐 기반 바이오 잉크 조성물 및 이를 이용하여 3차원 구조체를 제조하는 방법 | |
Blaeser et al. | Mikroventil-Basiertes 3D-Bioprinting-System Zum Additiven Aufbau Mit Lebenden Zellen Beladener Alginat-Strukturen | |
JP2006239093A (ja) | ケラチン多孔体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17806689 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018520931 Country of ref document: JP Kind code of ref document: A Ref document number: 20187034917 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017806689 Country of ref document: EP Effective date: 20190102 |